0001680367-23-000035.txt : 20230509 0001680367-23-000035.hdr.sgml : 20230509 20230509160900 ACCESSION NUMBER: 0001680367-23-000035 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230509 DATE AS OF CHANGE: 20230509 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Shattuck Labs, Inc. CENTRAL INDEX KEY: 0001680367 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 812575858 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-39593 FILM NUMBER: 23902025 BUSINESS ADDRESS: STREET 1: 500 W. 5TH STREET CITY: AUSTIN STATE: TX ZIP: 78701 BUSINESS PHONE: 512-900-4690 MAIL ADDRESS: STREET 1: 500 W. 5TH STREET CITY: AUSTIN STATE: TX ZIP: 78701 10-Q 1 sttk-20230331.htm 10-Q sttk-20230331
0001680367FALSE2023Q1December 31http://fasb.org/us-gaap/2022#LicenseMemberhttp://fasb.org/us-gaap/2022#LicenseMemberP4Y00016803672023-01-012023-03-3100016803672023-05-01xbrli:shares00016803672023-03-31iso4217:USD00016803672022-12-31iso4217:USDxbrli:shares00016803672022-01-012022-03-310001680367us-gaap:CommonStockMember2022-12-310001680367us-gaap:AdditionalPaidInCapitalMember2022-12-310001680367us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001680367us-gaap:RetainedEarningsMember2022-12-310001680367us-gaap:CommonStockMember2023-01-012023-03-310001680367us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310001680367us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310001680367us-gaap:RetainedEarningsMember2023-01-012023-03-310001680367us-gaap:CommonStockMember2023-03-310001680367us-gaap:AdditionalPaidInCapitalMember2023-03-310001680367us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310001680367us-gaap:RetainedEarningsMember2023-03-310001680367us-gaap:CommonStockMember2021-12-310001680367us-gaap:AdditionalPaidInCapitalMember2021-12-310001680367us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001680367us-gaap:RetainedEarningsMember2021-12-3100016803672021-12-310001680367us-gaap:CommonStockMember2022-01-012022-03-310001680367us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001680367us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001680367us-gaap:RetainedEarningsMember2022-01-012022-03-310001680367us-gaap:CommonStockMember2022-03-310001680367us-gaap:AdditionalPaidInCapitalMember2022-03-310001680367us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001680367us-gaap:RetainedEarningsMember2022-03-3100016803672022-03-31sttk:candidate0001680367sttk:OperatingAccountMember2023-03-310001680367us-gaap:MoneyMarketFundsMember2023-03-310001680367sttk:OperatingAccountMember2022-12-310001680367us-gaap:MoneyMarketFundsMember2022-12-310001680367us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001680367us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001680367us-gaap:RestrictedStockMember2023-01-012023-03-310001680367us-gaap:RestrictedStockMember2022-01-012022-03-310001680367us-gaap:USTreasurySecuritiesMember2023-03-310001680367us-gaap:USTreasurySecuritiesMember2022-12-3100016803672022-11-022022-11-020001680367sttk:A2020StockIncentivePlanMember2020-09-30xbrli:pure0001680367sttk:A2020StockIncentivePlanMember2023-01-012023-01-010001680367sttk:A2020StockIncentivePlanMember2023-03-310001680367sttk:A2020StockIncentivePlanMember2023-01-012023-03-31sttk:tranch0001680367sttk:A2020EmployeeStockPurchasePlanMember2020-10-140001680367sttk:A2020EmployeeStockPurchasePlanMember2020-10-142020-10-140001680367sttk:A2020EmployeeStockPurchasePlanMember2021-01-012021-01-010001680367sttk:A2020EmployeeStockPurchasePlanMember2023-01-012023-01-010001680367sttk:A2020EmployeeStockPurchasePlanMember2023-03-310001680367sttk:A2020EmployeeStockPurchasePlanMember2023-01-012023-03-310001680367sttk:A2020EmployeeStockPurchasePlanMember2022-01-012022-03-310001680367us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-03-310001680367us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-03-310001680367us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-03-310001680367us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-3100016803672022-01-012022-12-310001680367us-gaap:EmployeeStockOptionMember2023-01-012023-03-310001680367us-gaap:RestrictedStockUnitsRSUMember2022-12-310001680367us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-03-310001680367us-gaap:RestrictedStockUnitsRSUMember2023-03-310001680367sttk:A2020StockIncentivePlanMembersttk:BlackScholesOptionPricingModelMemberus-gaap:EmployeeStockOptionMember2023-01-012023-03-310001680367sttk:A2020StockIncentivePlanMembersttk:BlackScholesOptionPricingModelMemberus-gaap:EmployeeStockOptionMember2022-01-012022-03-310001680367sttk:A2020StockIncentivePlanMembersttk:MonteCarloOptionPricingModelMemberus-gaap:EmployeeStockOptionMember2023-01-012023-03-310001680367sttk:A2020StockIncentivePlanMembersttk:MonteCarloOptionPricingModelMemberus-gaap:EmployeeStockOptionMember2022-01-012022-03-310001680367us-gaap:EmployeeStockMembersttk:BlackScholesOptionPricingModelMembersttk:A2020EmployeeStockPurchasePlanMember2023-01-012023-03-310001680367us-gaap:EmployeeStockMembersttk:BlackScholesOptionPricingModelMembersttk:A2020EmployeeStockPurchasePlanMember2022-01-012022-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
FORM 10-Q
(Mark One)
☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2023
OR
☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from to
Commission File Number: 001-39593
Shattuck Labs, Inc.
(Exact name of registrant as specified in its charter)
Delaware
81-2575858
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification Number)
500 W. 5th Street, Suite 1200
Austin, TX 78701
(512) 900-4690
(Address of principal executive offices including zip code)
Former name, former address and former fiscal year, if changed since last report: N/A
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.0001 per shareSTTKThe Nasdaq Global Select Market
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
Large accelerated filer
☐
Accelerated filer
☐
Non-accelerated filer
☒
Smaller reporting company
☒
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒
As of May 1, 2023, the registrant had 42,471,288 shares of common stock, $0.0001 par value per share, outstanding.


SHATTUCK LABS, INC.
TABLE OF CONTENTS
Page
PART I1
Item 1.
1
1
2
3
4
5
16
Item 3.23
Item 4.23
PART II
24
Item 1.24
24
24
Item 3.24
Item 4.24
Item 5.24
25

26


CAUTIONARY NOTE ABOUT FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q contains “forward-looking statements” within the meaning of the federal securities laws, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts, including statements concerning our plans, objectives, goals, strategies, future events, future revenues or performance, financing needs, plans or intentions relating to products and markets, and business trends and other information referred to under the sections entitled “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. Forward-looking statements are not historical facts and reflect our current views with respect to future events. Given the significant uncertainties, you should not place undue reliance on these forward-looking statements.
There are a number of risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this Quarterly Report on Form 10-Q. Such risks, uncertainties and other factors include, among others, the following:
•the timing of the initiation, progress, and expected results of our nonclinical studies, our clinical trials, and our research and development programs;
•our ability to enroll patients in our clinical trials;
•the costs related to our nonclinical studies, our clinical trials and our research and development programs, and the impact of inflationary pressures on such costs;
•our ability to retain the continued service of our key executives and to identify, hire, and retain additional qualified professionals;
•our ability to advance product candidates into, and successfully complete, nonclinical studies and clinical trials;
•the timing or likelihood of regulatory filings and approvals;
•the commercialization of our product candidates, if approved;
•our ability and the potential to successfully manufacture and supply our product candidates for clinical trials and for commercial use, if approved;
•the pricing, coverage, and reimbursement of our product candidates, if approved;
•the implementation of our business model, strategic plans for our business, and product candidates;
•the scope of protection we are able to establish and maintain for intellectual property rights covering our technology platforms, including our ARC® and GADLEN™ product candidates and other product candidates, and the defense of such intellectual property rights;
•our potential need to obtain additional licenses of third-party technology that may not be available to us or are available only on commercially unreasonable terms, and which may cause us to operate our business in a more costly or otherwise adverse manner that was not anticipated;
•our ability to enter into strategic arrangements and/or collaborations and to realize the potential benefits of such arrangements;
•our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;
•our estimates regarding the market opportunity for our product candidates, if approved;
•our estimates regarding expenses, capital requirements, and needs for additional financing and our ability to obtain additional capital;
•our financial performance; and


•developments relating to our competitors and our industry, including competing product candidates and therapies.
There may be other factors that may cause our actual results to differ materially from the forward-looking statements expressed or implied in this Quarterly Report on Form 10-Q, including factors disclosed in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” You should evaluate all forward-looking statements made in this Quarterly Report on Form 10-Q in the context of these risks and uncertainties.
We caution you that the risks, uncertainties, and other factors referred to above and elsewhere in this Quarterly Report on Form 10-Q may not contain all of the risks, uncertainties and other factors that may affect our future results and operations. Moreover, new risks will emerge from time to time. It is not possible for our management to predict all risks. In addition, we cannot assure you that we will realize the results, benefits or developments that we expect or anticipate or, even if substantially realized, that they will result in the consequences or affect us or our business in the way expected.
Any forward-looking statements contained in this Quarterly Report on Form 10-Q speak only as of the date hereof and not of any future date, and we expressly disclaim any intent to update any forward-looking statements, whether as a result of new information, future events or otherwise.



PART I - FINANCIAL INFORMATION
Item 1. Condensed Financial Statements
SHATTUCK LABS, INC.
CONDENSED BALANCE SHEETS
(In thousands, except share and per share amounts)
March 31, 2023
December 31,
2022
(unaudited)
Assets
Current assets:
Cash and cash equivalents$66,043 $47,379 
Investments69,452 113,901 
Prepaid expenses and other current assets22,342 23,304 
Total current assets157,837 184,584 
Property and equipment, net16,887 17,671 
Other assets2,953 3,069 
Total assets$177,677 $205,324 
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable$5,128 $7,170 
Accrued expenses and other current liabilities10,881 17,795 
Total current liabilities16,009 24,965 
Non-current operating lease liabilities4,014 4,202 
Total liabilities20,023 29,167 
Commitments and contingencies (Note 5)
Stockholders’ equity:
Common stock, $0.0001 par value: 300,000,000 shares authorized; 42,460,258 shares issued and outstanding at March 31, 2023 and 42,390,586 shares issued and outstanding at December 31, 2022
5 5 
Additional paid-in capital397,724 396,041 
Accumulated other comprehensive loss(339)(877)
Accumulated deficit(239,736)(219,012)
Total stockholders’ equity157,654 176,157 
Total liabilities and stockholders’ equity$177,677 $205,324 
See accompanying notes to unaudited interim condensed financial statements
1

SHATTUCK LABS, INC.
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
(Unaudited)
(In thousands, except share and per share amounts)
 Three Months Ended March 31,
 20232022
Collaboration revenue$57 $— 
Operating expenses:
Research and development16,667 19,187 
General and administrative5,051 4,979 
Expense from operations21,718 24,166 
Loss from operations(21,661)(24,166)
Other income (expense)937 (362)
Net loss$(20,724)$(24,528)
Unrealized gain on investments538 33 
Comprehensive loss$(20,186)$(24,495)
Net loss per share – basic and diluted$(0.49)$(0.58)
Weighted-average shares outstanding – basic and diluted42,439,204 42,357,625 
See accompanying notes to unaudited interim condensed financial statements
2

SHATTUCK LABS, INC.
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY
(Unaudited)
(In thousands, except share amounts)
Three Months Ended March 31, 2023
Common StockAdditional Paid-In CapitalAccumulated Other Comprehensive Gain (Loss)Accumulated DeficitTotal Stockholders’ Equity
SharesAmount
Balance at December 31, 202242,390,586 $5 $396,041 $(877)$(219,012)$176,157 
Exercise of stock options and purchases pursuant to employee stock purchase plan11,888 — 39 — — 39 
Issuance of common stock upon settlement of restricted stock units73,937 — — — — — 
Shares withheld related to net share settlement(16,153)— (39)— — (39)
Stock-based compensation expense— — 1,683 — — 1,683 
Unrealized gain on investments— — — 538 — 538 
Net loss— — — — (20,724)(20,724)
Balance at Balance at March 31, 202342,460,258 $5 $397,724 $(339)$(239,736)$157,654 
Three Months Ended March 31, 2022
Common StockAdditional Paid-In CapitalAccumulated Other Comprehensive Gain (Loss)Accumulated DeficitTotal Stockholders’ Equity
SharesAmount
Balance at December 31, 202142,338,898 $5 $389,408 $(560)$(117,067)$271,786 
Exercise of stock options and purchases pursuant to employee stock purchase plan39,616 — 134 — — 134 
Stock-based compensation expense— — 1,513 — — 1,513 
Unrealized gain on investments— — — 33 — 33 
Net loss— — — — (24,528)(24,528)
Balance at March 31, 202242,378,514 $5 $391,055 $(527)$(141,595)$248,938 
See accompanying notes to unaudited interim condensed financial statements
3

SHATTUCK LABS, INC.
CONDENSED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
Three Months Ended
March 31,
20232022
Cash flows from operating activities:
Net loss$(20,724)$(24,528)
Adjustments to reconcile net loss to net cash used in operations:
Stock-based compensation1,683 1,513 
Depreciation1,014 472 
Non-cash operating lease expense85 65 
Net amortization (accretion) of investments(213)981 
Changes in operating assets and liabilities:
Prepaid expenses and other current assets1,462 3,699 
Other assets30 25 
Accounts payable(2,197)(7,738)
Accrued expenses and other current liabilities(7,356)(601)
Non-current operating lease liabilities(188)(165)
Deferred revenue(57)— 
Net cash used in operating activities(26,461)(26,277)
Cash flows from investing activities:
Purchases of property and equipment(75)(2,488)
Net change in investments45,200 (12,894)
Net cash provided by (used in) investing activities45,125 (15,382)
Cash flows from financing activities:
Proceeds from the exercises of stock options and purchases pursuant to employee stock purchase plan39 134 
Taxes paid related to net share settlement of equity awards(39)— 
Net cash provided by financing activities— 134 
Net increase (decrease) in cash and cash equivalents18,664 (41,525)
Cash and cash equivalents, beginning of period47,379 92,268 
Cash and cash equivalents, end of period$66,043 $50,743 
Supplemental disclosures of non-cash financial activities:
Operating lease liabilities recognized for operating right-of-use assets$— $5,447 
Operating right-of-use assets exchanged for operating lease liabilities$— $2,945 
Deferred revenue billed but not received$500 $— 
Unpaid amounts related to purchases of property and equipment$155 $319 

See accompanying notes to unaudited interim condensed financial statements
4

SHATTUCK LABS, INC.
NOTES TO THE UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS
1. Organization and Description of Business
Shattuck Labs, Inc. (the “Company”) was incorporated in 2016 in the State of Delaware and is a clinical-stage biopharmaceutical company developing dual-sided fusion proteins, including its Agonist Redirected Checkpoint (“ARC®”) and gamma delta T cell engager (“GADLEN™”) platforms, as novel classes of biologic medicines capable of multifunctional activity with potential applications in oncology and inflammatory diseases. Using its proprietary technology, the Company is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. The Company has one clinical-stage product candidate, SL-172154, and has several compounds in preclinical development.
Liquidity
The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $239.7 million as of March 31, 2023. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company’s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company’s cash and cash equivalents and investments of $135.5 million as of March 31, 2023 are sufficient to fund projected operations of the Company for at least the next twelve months.
Global Economic Considerations
In addition, the global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine and other political tensions, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on our future operations.
2. Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited interim condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).
Unaudited Interim Condensed Financial Statements
In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position, its results of operations, statements of changes in stockholders’ equity and cash flows for the interim periods presented. Operating results for interim periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The interim financial statements presented herein do not contain all required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed financial statements should be read in conjunction with the annual audited financial statements and related notes in our Annual Report on Form 10-K for the year ended December 31, 2022.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition,
5

the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management’s estimates.
Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one segment.
Fair Value of Financial Instruments
Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories:
•Level 1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date;
•Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
•Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Management believes that the carrying amounts of the Company’s financial instruments, including investments and accounts payable, approximate fair value due to the short-term nature of those instruments.
Concentration of Risk
Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. While the Company has not experienced any losses, the recent failure of Silicon Valley Bank (“SVB”), at which the Company held cash, exposed the Company to significant credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors. The Company is in the process of transferring its cash to an alternate depository institution, the financial position of which management believes does not expose the Company to significant credit risk. Where possible, the Company will also continue to hold its excess cash in investments and money market accounts to further limit exposure. The Company does not believe that it is subject to other unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value.
The Company is highly dependent on a limited number of contract manufacturing organizations (“CMOs”) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products.
6

The Company is highly dependent on a limited number of contract research organizations (“CROs”) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.
Cash and Cash Equivalents
The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents consisted of $0.8 million held in operating accounts and $65.2 million held in money market funds as of March 31, 2023, and $3.5 million held in operating accounts and $43.9 million held in money market funds as of December 31, 2022.
Investments
The Company’s investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income (loss), a component of stockholders’ equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. As of March 31, 2023 and December 31, 2022, there were no impairments related to credit losses of investments.
Impairment of Long-Lived Assets
Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were no impairments of long-lived assets for the three months ended March 31, 2023 and 2022.
Leases
The Company determines if an arrangement is a lease at inception. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The classification of the Company’s leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company’s operating leases is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirement of Accounting Standards Codification (“ASC”) 842, Leases of the Financial Accounting Standards Board (“FASB”) to leases with a term of 12 months or less for all classes of assets.
Commitments and Contingencies
The Company follows ASC 450-20, Contingencies of the FASB to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims
7

that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.
If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.
Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.
Revenue Recognition
Collaboration revenue is recognized in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.
Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below.
When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method.
The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed:
i.identify the contract(s) with a customer;
ii.identify the performance obligations in the contract;
iii.determine the transaction price;
iv.allocate the transaction price to the performance obligations within the contract; and
v.recognize revenue when (or as) the entity satisfies a performance obligation.
The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.
At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company’s arrangements may consist of a license of, or options to license, the Company’s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the
8

customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources and (ii) are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.
The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.
The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.
Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company’s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities.
The Company’s collaboration revenue arrangements may include the following:
Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances.
Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will
9

recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).
To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales.
Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, Research and Development. The Company considered the guidance in ASC 808, Collaborative Arrangements and will recognize the payments received from these agreements as revenue when the related costs are incurred.
Research and Development Costs
Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities.
A substantial portion of the Company’s ongoing research and development activities are conducted by third-party service providers, including CROs and CMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO or outside service provider, the payments will be recorded as a prepaid asset, which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company’s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company’s accruals that could materially affect the Company’s results of operations.
Net Loss Per Share
Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock or convertible notes, if any, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.
The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of March 31, 2023 and 2022, as they would be anti-dilutive:
Three Months Ended March 31,
20232022
Stock options5,261,439 3,460,911 
Unvested restricted stock652,598 313,390 
5,914,037 3,774,301 
Other Comprehensive Income (Loss)
Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on investments.
10

Recently Adopted Accounting Pronouncements
None.
3. Investments
The following table represents the Company’s available for sale investments by major security type (amounts in thousands):
March 31, 2023
Amortized
Cost		Gross Unrealized LossTotal Fair Value
Investments:
U.S. Treasury securities$69,791 $(339)$69,452 
Total investments$69,791 $(339)$69,452 
December 31, 2022
Amortized
Cost		Gross Unrealized LossTotal Fair Value
Investments:
U.S. Treasury securities$114,778 $(877)$113,901 
Total investments$114,778 $(877)$113,901 
 
The Company’s investment instruments and cash and cash equivalents are classified using Level 1 inputs within the fair value hierarchy and are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Debt securities have a weighted-average maturity of 0.24 years as of March 31, 2023.
4. Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following (amounts in thousands):
March 31,
2023		December 31,
2022
Research and development contract costs$6,650 $11,256 
Litigation settlement1,400 1,400 
Compensation and related benefits1,203 3,967 
Other current liabilities1,628 1,172 
Total accrued expenses and other current liabilities$10,881 $17,795 
5. Commitments and Contingencies
Operating Leases
The Company leases certain office space, laboratory facilities, and equipment. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has operating leases. There have been no material changes in our operating leases as compared to operating leases disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022.
11

Nighthawk Biosciences, Inc. License Agreement
In connection with a license agreement with Nighthawk Biosciences, Inc. (“Nighthawk”), the Company is required to make payments of up to $20.6 million in aggregate for the achievement of specified development, regulatory and commercial sales milestones for certain licensed products. The Company paid $0.1 million to Nighthawk in the three months ended March 31, 2023 as a milestone payment for the Company’s completion of a Phase 1 clinical trial for SL-172154. The Company is required to pay Nighthawk a percentage of upfront fees or other non-royalty payments not tied to milestone events that it receives in connection with certain sublicenses of the licensed patents. The Company is also required to pay Nighthawk a royalty on all of its worldwide net sales, those of its affiliates, and sublicenses of certain licensed patents in the low single digits. The Company has not recorded a liability for the aforementioned payments given the achievement of specified development, regulatory and commercial sales milestones for certain licensed products is not probable as of the balance sheet date.
Litigation
From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. On January 31, 2022 and February 11, 2022, putative class action lawsuits were filed in the U.S. District Court for the Eastern District of New York against us and certain of the Company’s officers and directors. The cases were consolidated on June 2, 2022, and the plaintiffs filed an amended complaint on July 1, 2022. The amended complaint cites the volatility in the Company’s common stock and alleges that the defendants made or are responsible for misleading omissions regarding the Company’s clinical trial results and the collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company, Ltd. The parties reached a settlement in principle of the plaintiffs’ claims in the amount of $1.4 million on November 2, 2022. The settlement is subject to a definitive settlement agreement, notice to stockholders and court approval. The parties filed their motion for preliminary approval of the settlement agreement with the court on December 14, 2022, and, as of May 8, 2023, that motion is pending. The Company has accrued the settlement amount in accrued expenses and other current liabilities as of March 31, 2023.
Contractual Obligations
Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company’s contractual obligations result primarily from obligations for various CMOs and CROs, which include potential payments that may be required under its agreements. The contracts also contain variable costs and milestones that are hard to predict, as they are based on such things as patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under CMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Such agreements are cancellable upon written notice by the Company and, therefore, are not long-term liabilities.
6. Equity
The Company is authorized to issue up to 300,000,000 shares of common stock and 10,000,000 shares of preferred stock, all with a par value of $0.0001 per share. The holders of the Company’s common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. The Company’s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of the Company’s common stock will receive ratably any dividends declared by the Company’s board of directors (“Board”) out of funds legally available. In the event of the Company’s liquidation, dissolution or winding-up, the holders of the Company’s common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. As of the periods presented, no common stock dividends had been declared by the Board. At March 31, 2023, none of the 10,000,000 shares of preferred stock were outstanding, and the Company has no present plans to issue any shares of preferred stock.
7. Stock-Based Compensation
2020 Equity Incentive Plan
In September 2020, the Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”) which, as of the adoption date, replaced the 2016 Stock Incentive Plan. Under the 2020 Plan, the share reserve automatically
12

increases on January 1st of each year beginning in 2021 and ending with a final increase on January 1, 2030 in an amount equal to 4% of the Company’s outstanding common shares on December 31st of the preceding calendar year. The Board may provide that there will be no increase in the share reserve for any such year or that the increase in the share reserve may be smaller than would otherwise occur. On January 1, 2023, the share reserve automatically increased by 1,695,623 shares. As of March 31, 2023, there were 3,739,124 shares available for future grants. The 2020 Plan permits the granting of options, stock appreciation rights, restricted stock units (“RSUs”), performance stock and performance cash awards. The terms of the agreements under the 2020 Plan are determined by the Board. The Company’s awards generally vest over four years and have a term of 10 years. In 2023, the Company granted 165,050 awards that vest in three equal tranches based on the Company achieving a certain closing share price for each tranche for 30 consecutive trading days on or before the fourth anniversary of the grant date.
2020 Employee Stock Purchase Plan
The 2020 Employee Stock Purchase Plan (“2020 ESPP”) became effective in October 2020. A total of 395,795 shares of common stock were reserved for issuance under the 2020 ESPP. Eligible employees may purchase shares of common stock under the 2020 ESPP at 85% of the lower of the fair market value of the Company’s common stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee’s eligible compensation and may not purchase more than $25,000 of stock during any calendar year or more than 600 shares during any one purchase period. The 2020 ESPP share reserve automatically increases on January 1st of each calendar year, for ten years, commencing on January 1, 2021, in an amount equal to 1% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Board may act prior to January 1st of a given year to provide that there will be no January 1st increase of the share reserve for such year or that the increase in the share reserve for such year will be a smaller number of shares of common stock than would otherwise occur pursuant to the preceding sentence. On January 1, 2023, the share reserve increased by 423,905 shares. As of March 31, 2023, there were 1,216,723 shares available for future grants. During the three months ended March 31, 2023 and 2022, the Company issued 11,171 and 5,227 shares of common stock for aggregate cash proceeds of $0.1 million and $0.1 million, respectively.
The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim condensed statements of operations and comprehensive loss (in thousands):
Three Months Ended March 31,
20232022
Research and development$814 $827 
General and administrative869 686 
Total stock-based compensation$1,683 $1,513 
The following table summarizes option activity under the 2020 Plan:
Options
Weighted
Average
Exercise Price
Weighted
Average
Remaining Life
(Years)
Balance at December 31, 20224,209,255 $8.29 8.07
Granted1,181,087 3.57 
Exercised(717)2.95 
Forfeited(128,186)7.57 
Balance at March 31, 20235,261,439 $7.25 8.07
Vested and expected to vest5,174,691 $7.27 8.05
Exercisable at the end of the period2,122,655 $8.28 6.55
Options granted during the three months ended March 31, 2023 and 2022 had weighted-average grant-date fair values of $2.46 and $5.13 per share, respectively. As of March 31, 2023, the unrecognized compensation cost for options issued was $14.1 million and will be recognized over an estimated weighted-average amortization period of 2.49 years. The total intrinsic value of options exercised during the three months ended March 31, 2023 and 2022
13

was $0.1 million and $0.1 million, respectively. The aggregate intrinsic value of options outstanding and exercisable as of March 31, 2023 was $0.2 million.
Restricted Stock Units
The following table summarizes employee RSU activity for the three months ended March 31, 2023:
Awards
Weighted
Average
Grant Date Fair Value
Unvested RSUs as of December 31, 2022309,477 $7.22 
Granted445,025 3.57 
Released(73,937)7.43 
Forfeited(27,967)4.89 
Balance at March 31, 2023
652,598 $4.81 
The Company recognized $0.2 million of stock-based compensation related to RSUs as of March 31, 2023. As of March 31, 2023, the unrecognized compensation cost for RSUs issued was $3.1 million and will be recognized over an estimated weighted-average amortization period of 3.47 years. The fair values of RSUs are based on the fair value of the Company’s common stock on the date of the grant.
Fair Value of Stock Options and Shares Issued
The Company accounts for stock-based compensation by measuring and recognizing as compensation expense the fair value of all share-based payment awards made to employees, including employee stock options and restricted stock awards. The Company uses the Black-Scholes option pricing model to estimate the fair value of employee stock options that only have service or performance conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The inputs to both pricing models require a number of management estimates such as the expected term, volatility, risk-free interest rate and dividend yield. The fair value of stock options was determined using the methods and assumptions discussed below.
•The expected term of employee stock options with service-based vesting is determined using the “simplified” method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company’s lack of sufficient historical data.
•The expected stock price volatility assumption is based on the historical volatilities of the common stock of a peer group of publicly traded companies as well as the historical volatility of the Company’s common stock since the Company began trading subsequent to the Company’s initial public offering (“IPO”) in October 2020 over the period corresponding to the expected life as of the grant date. The historical volatility data was computed using the daily closing prices during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company’s stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. In the latter case, other suitable, similar entities whose share prices are publicly available would be utilized in the calculation.
•The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term.
•The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay dividends on its common stock.
•Prior to the Company’s IPO, the Board periodically estimated the fair value of the Company’s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. Subsequent to the Company’s IPO, options are issued with a strike price no less than the market price on date of grant.
14

The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company’s 2020 Plan were estimated using the following weighted-average assumptions:
Three Months Ended March 31,
20232022
2020 Plan
Expected term - years6.086.08
Expected volatility84.8%81.9%
Risk-free interest rate3.5%1.6%
Expected dividends——
The grant-date fair value of options calculated using the Monte Carlo option pricing model granted under the Company’s 2020 Plan were estimated using the following assumptions:
Three Months Ended March 31,
20232022
2020 Plan
Expected term - years4.004.00
Expected volatility80.0%80.0%
Risk-free interest rate3.6%1.4%
Expected dividends——
The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company’s 2020 ESPP were estimated using the following weighted-average assumptions:
Three Months Ended March 31,
20232022
2020 ESPP
Expected term - years0.490.49
Expected volatility84.8%81.8%
Risk-free interest rate3.5%2.0%
Expected dividends——
15

 
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
You should read the following discussion and analysis of our financial condition and results of operations together with our unaudited condensed financial statements and related notes appearing in this Quarterly Report on Form 10-Q, as well as the audited financial statements, notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2022. This discussion and other parts of this Quarterly Report on Form 10-Q contain forward-looking statements that involve risks and uncertainties, such as statements of our plans, objectives, expectations and intentions. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the “Risk Factors” section of our Annual Report on Form 10-K. You should carefully read the “Cautionary Note About Forward-Looking Statements” of this Quarterly Report on Form 10-Q and the “Risk Factors” section of our Annual Report on Form 10-K to gain an understanding of the important factors that could cause actual results to differ materially from the results described below.
Overview
We are an innovative clinical-stage biotechnology company pioneering the development of dual-sided fusion proteins as an entirely new class of biologic medicine. We have created a novel approach to immune modulation by designing biologics with structural characteristics that may not be achievable by existing therapeutic modalities, including monoclonal or bispecific antibodies. Compounds derived from our proprietary Agonist Redirected Checkpoint, or ARC®, platform simultaneously inhibit checkpoint molecules and activate costimulatory molecules with a single therapeutic.
Our lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPα macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. Coupling CD40 activation with CD47 inhibition differentiates SL-172154 from all other clinical-stage CD47/SIRPα inhibitors in development, and in our published preclinical studies, SL-172154 resulted in superior antitumor immunity as compared to certain CD47/SIRPα inhibitors. We are pursuing a broad clinical development strategy in both solid and hematologic tumors, with multiple ongoing clinical trials. SL-172154 is in an ongoing Phase 1 clinical trial for the treatment of patients with ovarian cancer. We are also evaluating SL-172154 in an ongoing Phase 1 clinical trial for the treatment of patients with certain hematologic malignancies, including acute myeloid leukemia, or AML, and higher-risk myelodysplastic syndromes, or HR-MDS. We believe our clinical development plan may provide both first-in-class and best-in-class development opportunities for SL-172154.
We believe that data shared to date in human cancer patients have demonstrated that the unique protein engineering and physical properties of the ARC platform have led to a differentiated profile in terms of safety and on-target immune activation, demonstrated by unique pharmacodynamic findings, as compared to monoclonal or bispecific antibodies.
In addition to our clinical-stage ARC product candidate, we possess a deep pipeline of potential product candidates in preclinical development. As an example, SL-9258, an ARC compound in preclinical development, is designed to inhibit the TIGIT/PVR checkpoint interaction while simultaneously activating HVEM and LTβ costimulatory receptors.
Furthermore, our expertise in dual-sided fusion proteins has led to the development of a second novel platform technology. We call this our gamma delta T cell engager, or GADLEN™, platform. The most advanced compounds from this platform are a CD20-directed GADLEN and a B7-H3-directed GADLEN.
Longer-term, we are pursuing additional disease areas, including autoimmune diseases, where our dual-sided fusion protein platforms may provide advantages over current treatment modalities.
Overview of Operations
Since our inception in 2016, we have devoted substantially all of our resources to conducting research and development activities, including undertaking nonclinical studies of our product candidates, conducting clinical trials of our most advanced product candidates, manufacturing our product candidates, developing and perfecting our intellectual property rights, organizing and staffing our company, business planning and raising capital. We do not have any products approved for sale, and we have not generated any revenue from product sales. We have
16

funded our operations as of the filing date of this Quarterly Report on Form 10-Q through the net proceeds from our initial public offering, or IPO, of approximately $213.5 million, the sale of redeemable convertible preferred stock for approximately $152.9 million, the issuance of convertible notes for approximately $10.5 million and payments received pursuant to our collaboration agreements for approximately $82.7 million.
For the three months ended March 31, 2023 and 2022, our net loss was $20.7 million and $24.5 million, respectively. We have not been profitable since inception, and as of March 31, 2023, we had an accumulated deficit of $239.7 million and $135.5 million in cash and cash equivalents and investments. We expect to continue to incur significant expenses and operating losses in the near term in connection with our ongoing activities, as we:
•continue to advance the nonclinical and clinical development of our clinical-stage product candidate, SL-172154;
•initiate nonclinical studies and clinical trials for additional product candidates that we may identify in the future;
•manufacture sufficient quantities of bulk drug substance and drug product to support our ongoing and planned nonclinical studies and clinical trials;
•continue our process development efforts for our current and future product candidates;
•maintain our operational, financial, and management systems;
•retain key personnel and infrastructure to support our clinical development, research and manufacturing efforts;
•utilize our in-house process development and manufacturing capabilities;
•continue to develop, perfect, and defend our intellectual property portfolio; and
•incur additional legal, accounting, or other expenses in operating our business, including the additional costs associated with operating as a public company and expenses incurred in connection with ongoing and future litigation, if any.
We do not expect to generate significant product revenue unless and until we successfully complete development and obtain regulatory and marketing approval of, and begin to sell, one or more of our product candidates, if ever, which we expect will take several years. We expect to spend a significant amount in development and marketing costs prior to such time. We may never succeed in achieving regulatory and marketing approval for our product candidates. We may obtain unexpected results from our nonclinical studies and clinical trials. We may elect to discontinue, delay, or modify nonclinical studies and clinical trials of our product candidates. We may be adversely affected by inflationary pressures and the macroeconomic environment, which are beyond our control. A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. Accordingly, until such time as we can generate significant product revenue, if ever, we expect to continue to seek private or public equity and debt financing, and/or additional collaborations with third-parties, to meet our capital requirements. There can be no assurance that such funding may be available to us on acceptable terms, or at all, or that we will be able to commercialize our product candidates. In addition, we may not be profitable even if we commercialize any of our product candidates.
Global Economic Considerations
In addition, the global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine and other political tensions, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on our future operations.
17

Components of our Results of Operation
Collaboration Revenue
We have no products approved for commercial sale, and we have not generated any revenue from commercial product sales. Our total revenue to date has been generated from our collaboration and research agreements with various third parties, including a clinical trial collaboration agreement with ImmunoGen, Inc., or ImmunoGen, under which we expect to recognize up to $2.0 million of revenue, beginning in 2023 and continuing into or through 2024.
We continue to explore other potential collaborations and expect that collaboration revenue we may generate, if any, will fluctuate from period to period.
Operating Expense
Research and Development Expense
Our research and development expenses consist primarily of costs incurred in connection with the discovery and development of our current and potential future product candidates. These expenses include:
•expenses incurred to conduct our nonclinical studies and clinical trials;
•costs of manufacturing nonclinical study and clinical trial materials, including the costs of raw materials required for manufacturing;
•process development activities to optimize manufacturing processes;
•employee-related expenses, including salaries, benefits, and stock-based compensation;
•laboratory materials and supplies used to support our research activities;
•fees paid to third parties who assist with research and development activities;
•expenses relating to regulatory activities, including filing fees paid to regulatory agencies; and
•allocated expenses for facility-related costs.
The following table summarizes our research and development expenses by product candidate:
Three Months Ended March 31,
(in thousands)
2023
2022
(unaudited)
SL-172154$5,967 $8,182 
Other pipeline compounds3,429 5,280 
Internal costs, including personnel related benefits, facilities and depreciation7,271 5,725 
$16,667 $19,187 
Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials, including increased demand for clinical trial material. We expect to incur significant research and development expenses throughout 2023. While it is difficult for us to predict with certainty, we expect increasing year-over-year operating expense over the next several years in the event that we conduct additional nonclinical studies and clinical trials (beyond our currently planned clinical trials), including later-stage clinical trials, for our current and future product candidates, pursue regulatory approval of our product candidates, or advance our preclinical pipeline.
The process of conducting the necessary nonclinical and clinical research to obtain regulatory approval is costly and time consuming. The actual probability of success for our product candidates may be affected by a variety of factors including:
•the safety and efficacy of our product candidates;
•early clinical data for our product candidates;
18

•investment in our clinical programs;
•competition;
•manufacturing capability; and
•commercial viability.
We may never succeed in achieving regulatory approval for any of our product candidates due to the uncertainties discussed above. We are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate revenue from the commercialization and sale of our product candidates, if ever.
General and Administrative Expense
General and administrative expense consists primarily of personnel expenses, including salaries, benefits, and stock-based compensation expense, for employees and consultants in executive, finance, accounting, legal, information technology, business development and human resource functions. General and administrative expense also includes corporate facility costs, including rent, utilities, depreciation, and maintenance, not otherwise included in research and development expense, as well as legal fees related to intellectual property, corporate, and litigation matters and fees for accounting and tax services.
We expect that our general and administrative expense may increase in the future to support our ongoing research and development activities and as a result of the costs of operating as a public company. These increases may include increased costs related to the retention of personnel and fees paid to outside consultants, lawyers, and accountants, among other expenses. Additionally, we anticipate that we will continue to incur significant costs associated with being a public company, including expenses related to services associated with maintaining compliance with the requirements of Nasdaq and the Securities and Exchange Commission, or SEC, insurance, and investor relations costs. If any of our current or future product candidates advances to later-stage clinical development or obtains regulatory approval, we expect that we would incur significantly increased expenses associated with building the appropriate general and administrative support for our increased research and development activities, or building a sales and marketing team, respectively.
Other Income
Other income consists of interest earned on our cash, cash equivalents and investments, which consists of amounts held in a money market fund and at various times in government obligations as well as investment fees and realized gain or losses on investments (if any).
Income Taxes
Since our inception, we have not recorded any income tax benefits for the net operating losses, or NOLs, we have incurred or for our research and development tax credits, as we believe, based upon the weight of available evidence, that it is more likely than not that all of our NOLs and tax credits will not be realized. Our NOLs and tax credit carryforwards will begin to expire in 2024. We have recorded a full valuation allowance against our deferred tax assets at each balance sheet date.
19

Results of Operations
Comparison of the Three Months Ended March 31, 2023 and 2022
The following table sets forth our results of operations for the three months ended March 31, 2023 and 2022.
Three Months Ended March 31,
Change
(in thousands)20232022DollarPercentage
(unaudited)
Collaboration revenue$57 $— $57 100.0 %
Operating expenses:
Research and development16,667 19,187 (2,520)(13.1)%
General and administrative5,051 4,979 72 1.4 %
Loss from operations(21,661)(24,166)2,505 (10.4)%
Other income (expense):
Other937 (362)1,299 358.8 %
Net loss$(20,724)$(24,528)$3,804 (15.5)%
Collaboration Revenue
Collaboration revenue increased by $0.1 million, or 100.0%, to $0.1 million for the three months ended March 31, 2023 from none for the three months ended March 31, 2022. The increase in revenue was attributable to an increase in clinical activity associated with our clinical trial collaboration agreement with ImmunoGen, under which we expect to recognize up to $2.0 million of revenue through 2024.
Research and Development Expense
Research and development expenses decreased by $2.5 million, or (13.1)%, to $16.7 million for the three months ended March 31, 2023 from $19.2 million for the three months ended March 31, 2022. The decrease in research and development cost was primarily a result of a decrease in the good manufacturing practice manufacture of clinical trial material of $7.0 million offset by increases in costs associated with the conduct of clinical trials for SL-172154 of $1.6 million, employee compensation and benefits of $1.0 million, facility and depreciation costs related to the 2022 expansion of our in-house manufacturing and development capabilities of $1.0 million and research and development costs related to other pipeline candidates of $0.8 million.
General and Administrative Expense
General and administrative expenses remained relatively unchanged for the three months ended March 31, 2023 as compared to the three months ended March 31, 2022.
Liquidity and Capital Resources
Since our inception, our primary sources of liquidity have been generated by sales of our preferred stock and common stock, including our IPO, and through our collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company, Ltd., or Takeda. As of March 31, 2023, we had an accumulated deficit of $239.7 million and $135.5 million of cash and cash equivalents and investments.
In July 2022, we entered into a sales agreement, or the Sales Agreement, with SVB Securities LLC, or the Sales Agent, pursuant to which we may offer and sell up to $75.0 million of shares of our common stock from time to time in the ATM Facility. The Sales Agent is generally entitled to compensation at a commission equal to 3.0% of the aggregate gross sales price per share sold under the Sales Agreement. As of March 31, 2023, there were no sales pursuant to the ATM Facility.
Capital Resources and Funding Requirements
Our primary uses of cash and cash equivalents and investments are to fund our operations, which consist primarily of research and development expenditures related to our programs, product development costs, research expenses, administrative support, capital expenditures related to bringing in-house certain process development and manufacturing capabilities and working capital requirements. We anticipate incurring additional net losses and
20

negative cash flows from operations in the near future until such time, if ever, that we can generate significant sales of our product candidates currently in development. Our future funding requirements will depend on many factors, including:
•the scope, timing, progress and results of discovery, nonclinical development, laboratory testing, and clinical trials for our product candidates;
•the costs of process development and scale up of a commercially ready manufacturing process to support registrational clinical trials;
•the costs of manufacturing our product candidates for clinical trials and in preparation for marketing approval and commercialization;
•the extent to which we enter into collaborations or other arrangements with additional third parties in order to further develop our product candidates;
•the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending other intellectual property-related claims;
•the costs and fees associated with the discovery, acquisition or in-license of additional product candidates or technologies;
•the costs of future commercialization activities, if any, including establishing sales, marketing, manufacturing, distribution and storage capabilities, for any of our product candidates for which we receive marketing approval; and
•revenue, if any, received from commercial sales of our product candidates, should any of our product candidates receive marketing approval.
Until we obtain regulatory approval to market our product candidates, if ever, we cannot generate revenues from sales of our products. Even if we are able to sell our products, we may not generate a sufficient amount of product revenues to finance our cash requirements. Accordingly, it will be necessary for us to seek to raise additional capital through equity offerings and/or debt financings or from other potential sources of liquidity, which may include new collaborations, licensing or other commercial agreements for one or more of our development programs or patent portfolios. There can be no assurance that such funding may be available to us on acceptable terms, or at all. The issuance of equity securities may result in dilution to stockholders and the issuance of debt securities may have rights, preferences and privileges senior to those of our common stock and the terms of any such debt securities could impose significant restrictions on our operations. The failure to raise funds as and when needed could have a negative impact on our financial condition and ability to pursue our business strategies. Additionally, if additional funding is not secured when required, we may need to delay or curtail our operations until such funding is received, which would have a material and adverse impact on our business prospects and results of operations.
We believe that our cash and cash equivalents and investments as of March 31, 2023 are sufficient to fund projected operations through year-end 2024.
Cash Flows
The following table shows a summary of our cash flows for the periods indicated:
Three Months Ended March 31,
(in thousands)20232022
(unaudited)
Net cash used in operating activities$(26,461)$(26,277)
Net cash provided by (used in) investing activities45,125 (15,382)
Net cash provided by financing activities— 134 
Net increase (decrease) in cash and cash equivalents$18,664 $(41,525)
Net Cash Used in Operating Activities
During the three months ended March 31, 2023, net cash used in operating activities was $26.5 million and primarily reflected our net loss of $20.7 million and a $8.3 million net change in our operating assets and liabilities,
21

offset by noncash charges of $1.7 million in stock-based compensation, and $0.8 million in depreciation expense, accretion of investments and non-cash operating lease expense. We expect to continue to use cash in our operating activities as we conduct our clinical trials and nonclinical studies, incur costs of manufacturing clinical trial and nonclinical study materials and continue process development activities to optimize our manufacturing processes.
During the three months ended March 31, 2022, net cash used in operating activities was $26.3 million and primarily reflected our net loss of $24.5 million and a $4.8 million net change in our operating assets and liabilities, offset by noncash charges of $1.5 million in stock-based compensation and $1.5 million in depreciation expense, amortization of investments and non-cash operating lease expense.
Net Cash Provided by (Used in) Investing Activities
During the three months ended March 31, 2023, net cash provided by investing activities was $45.1 million, of which $45.2 million represents the net change in investments and $0.1 million was used to purchase property and equipment, primarily attributable to our continued efforts to bring in-house certain process development, manufacturing and laboratory capabilities.
During the three months ended March 31, 2022, net cash used in investing activities was $15.4 million, of which $12.9 million represents the net change in investments and $2.5 million was used to purchase property and equipment.
Net Cash Provided by Financing Activities
During the three months ended March 31, 2022, net cash provided by financing activities was $0.1 million and was primarily from the exercise of stock options and purchases pursuant to our employee stock purchase plan.
Contractual Obligations and Other Commitments
See Note 5 to our financial statements found elsewhere in this Quarterly Report on Form 10-Q for additional disclosures. There have been no other material changes from the Contractual Obligations and Other Commitments disclosed in Note 6 and 7 of our Annual Report on Form 10-K for the year ended December 31, 2022.
Critical Accounting Policies
Our management’s discussion and analysis of our financial condition and results of operations are based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in
the United States of America, or GAAP. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in our financial statements. On an ongoing basis, we evaluate our estimates and judgments, including those related to revenue recognition, the accrual for research and development expenses, and the valuation of stock-based awards. We base our estimates on historical experience, known trends and events, and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.
Our critical accounting policies are those policies which require the most significant judgments and estimates in the preparation of our financial statements. We believe that the assumptions and estimates associated with our most critical accounting policies are those relating to revenue, accrued research and development costs and stock-based compensation.
There have been no material changes in our critical accounting policies and estimates as compared to the critical accounting policies and estimates disclosed in Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the year ended December 31, 2022.
Recent Accounting Pronouncements
See Note 2 to our financial statements found elsewhere in this Quarterly Report on Form 10-Q for a description of recent accounting pronouncements applicable to our financial statements.
22

Emerging Growth Company and Smaller Reporting Company Status
We are an emerging growth company as defined in the JOBS Act. Under the JOBS Act, an emerging growth company can take advantage of the extended transition period for complying with new or revised accounting standards and delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption from complying with new or revised accounting standards and, therefore, will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.
We have evaluated the benefits of relying on other exemptions and reduced reporting requirements under the JOBS Act. Subject to certain conditions, as an emerging growth company, we may rely on certain of these exemptions, including without limitation exemptions to the requirements for (1) providing an auditor’s attestation report on our system of internal controls over financial reporting pursuant to Section 404(b) of the Sarbanes-Oxley Act and (2) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor’s report providing additional information about the audit and the financial statements, known as the auditor discussion and analysis. We will remain an emerging growth company until the earlier of (a) the last day of the fiscal year (i) following the fifth anniversary of the completion of our IPO, (ii) in which we have total annual gross revenues of at least $1.235 billion or (iii) in which we are deemed to be a “large accelerated filer” under the rules of the SEC, which means the market value of our common stock that is held by non-affiliates exceeds $700.0 million as of the prior June 30th, or (b) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.
We are also a “smaller reporting company” as defined under the Securities and Exchange Act of 1934, as amended, or the Exchange Act. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue is less than $100.0 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700.0 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
We are a smaller reporting company, as defined by Rule 12b-2 under the Exchange Act and in Item 10(f)(1) of Regulation S-K, and are not required to provide the information under this item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Our management, with the participation of our principal executive officer and our principal financial officer, evaluated, as of the end of the period covered by this Quarterly Report on Form 10-Q, the effectiveness of our disclosure controls and procedures. Based on this evaluation of our disclosure controls and procedures as of March 31, 2023, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures as of such date are effective at the reasonable assurance level. The term “disclosure controls and procedures,” as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act are recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures.
23

Changes in Internal Control over Financial Reporting
There were no changes in our internal control over financial reporting during the first quarter of the year ending December 31, 2023 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II - OTHER INFORMATION
Item 1. Legal Proceedings
Except as discussed in Note 5 to our financial statements found elsewhere in this Quarterly Report on Form 10-Q, we are not presently a party to any other legal proceedings that, in the opinion of our management and if determined adversely to us, would individually or taken together have a material adverse effect on our business, operating results, financial condition or cash flows.
Item 1A. Risk Factors
Our business is subject to various risks, including those described in Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes from the risk factors disclosed in Item 1A of our Annual Report on Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
None.
Item 4. Mine Safety Disclosures
None.
Item 5. Other Information
None.
24

Item 6. Exhibits
The exhibits filed or furnished as part of this Quarterly Report on Form 10-Q are set forth below.
Exhibit
Number		Description of Exhibit
  
3.1
3.2
4.1
  
4.2
31.1*
  
31.2*
  
32.1* (1)
101.INS*Inline XBRL Instance Document
101.SCH*Inline XBRL Taxonomy Extension Schema Document
101.CAL*Inline XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*Inline XBRL Taxonomy Extension Definition
101.LAB*Inline XBRL Taxonomy Extension Label Linkbase Document
101.PRE*Inline XBRL Taxonomy Extension Presentation Linkbase Document
104*The cover page for this report, formatted in Inline XBRL (included in Exhibit 101)
______________
*    Filed herewith
(1)    The certifications on Exhibit 32 hereto are deemed not “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that Section. Such certifications will not be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
25

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Shattuck Labs, Inc.
 
Date: May 9, 2023By:
/s/ Dr. Taylor Schreiber
 
Dr. Taylor Schreiber
Chief Executive Officer
(principal executive officer)
Date: May 9, 2023By:
/s/ Andrew R. Neill
Andrew R. Neill
Chief Financial Officer
(principal financial and accounting officer)

26
 EX-31.1 2 sub-certxsection302xceoxq1.htm EX-31.1 Document

Exhibit 31.1
CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Taylor Schreiber, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Shattuck Labs, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 9, 2023By:
/s/ Dr. Taylor Schreiber
 
Dr. Taylor Schreiber
Chief Executive Officer
(principal executive officer)

 EX-31.2 3 sub-certxsection302xcfoxq1.htm EX-31.2 Document

Exhibit 31.2
CERTIFICATION PURSUANT TO RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES
EXCHANGE ACT OF 1934, AS ADOPTED PURSUANT TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002
I, Andrew R. Neill, certify that:
1.I have reviewed this Quarterly Report on Form 10-Q of Shattuck Labs, Inc.;
2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4.
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
 a.
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5.The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
 a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.


Date: May 9, 2023By:
/s/ Andrew R. Neill
Andrew R. Neill
Chief Financial Officer
(principal financial and accounting officer)

 EX-32.1 4 sub-certxsection906ofthesa.htm EX-32.1 Document


Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report on Form 10-Q of Shattuck Labs, Inc. (the “Company”) for the period ended March 31, 2023 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge:
(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 9, 2023By:/s/ Dr. Taylor Schreiber
Dr. Taylor Schreiber
Chief Executive Officer
(principal executive officer)

Date: May 9, 2023By:/s/ Andrew R. Neill
Andrew R. Neill
Chief Financial Officer
(principal financial and accounting officer)

The foregoing certification is being furnished solely to accompany the Report pursuant to 18 U.S.C. §1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, and is not to be incorporated by reference into any filing of the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.
Note: A signed original of this written statement required by §906 has been provided to Shattuck Labs, Inc. and will be retained by Shattuck Labs, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.



 EX-101.SCH 5 sttk-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - COVER link:presentationLink link:calculationLink link:definitionLink 0000002 - Statement - CONDENSED BALANCE SHEETS link:presentationLink link:calculationLink link:definitionLink 0000003 - Statement - CONDENSED BALANCE SHEETS - Parenthetical link:presentationLink link:calculationLink link:definitionLink 0000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS link:presentationLink link:calculationLink link:definitionLink 0000005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY link:presentationLink link:calculationLink link:definitionLink 0000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS link:presentationLink link:calculationLink link:definitionLink 0000007 - Disclosure - Organization and Description of Business link:presentationLink link:calculationLink link:definitionLink 0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 0000009 - Disclosure - Investments link:presentationLink link:calculationLink link:definitionLink 0000010 - Disclosure - Accrued Expenses and Other Current Liabilities link:presentationLink link:calculationLink link:definitionLink 0000011 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 0000012 - Disclosure - Equity link:presentationLink link:calculationLink link:definitionLink 0000013 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 0000014 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 0000015 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) link:presentationLink link:calculationLink link:definitionLink 0000016 - Disclosure - Investments (Tables) link:presentationLink link:calculationLink link:definitionLink 0000017 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) link:presentationLink link:calculationLink link:definitionLink 0000018 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 0000019 - Disclosure - Organization and Description of Business (Details) link:presentationLink link:calculationLink link:definitionLink 0000020 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details) link:presentationLink link:calculationLink link:definitionLink 0000022 - Disclosure - Investments - Schedule of available for sale investments (Details) link:presentationLink link:calculationLink link:definitionLink 0000023 - Disclosure - Investments - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000024 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of accrued expenses and other current liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 0000025 - Disclosure - Commitments and Contingencies - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000026 - Disclosure - Equity (Details) link:presentationLink link:calculationLink link:definitionLink 0000027 - Disclosure - Stock-Based Compensation - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 0000028 - Disclosure - Stock-Based Compensation - Schedule of stock-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 0000029 - Disclosure - Stock-Based Compensation - Schedule of option activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000030 - Disclosure - Stock-Based Compensation - Schedule of restricted stock activity (Details) link:presentationLink link:calculationLink link:definitionLink 0000031 - Disclosure - Stock-Based Compensation - Schedule of valuation assumptions (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 sttk-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 sttk-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 sttk-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Operating Account Operating Account [Member] Operating Account Adjustments to reconcile net loss to net cash used in operations: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Increase in number of shares authorized, percentage of capital stock outstanding Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage Income Statement [Abstract] Options, granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Entity Address, Postal Zip Code Entity Address, Postal Zip Code Additional Paid-In Capital Additional Paid-in Capital [Member] Document Fiscal Period Focus Document Fiscal Period Focus Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value 2020 Employee Stock Purchase Plan 2020 Employee Stock Purchase Plan [Member] 2020 Employee Stock Purchase Plan Cash and Cash Equivalents Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block] Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding Weighted-average shares outstanding – diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Unrealized gain on investments Unrealized gain on investments Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent Expected term - years Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Maximum number of shares per employee during any one purchase period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee Schedule of RSU activity Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block] Revenue from Contract with Customer, Product and Service [Extensible List] Revenue from Contract with Customer, Product and Service [Extensible Enumeration] Debt Securities, Available-for-sale [Line Items] Debt Securities, Available-for-Sale [Line Items] Common stock, $0.0001 par value: 300,000,000 shares authorized; 42,460,258 shares issued and outstanding at March 31, 2023 and 42,390,586 shares issued and outstanding at December 31, 2022 Common Stock, Value, Issued Additional paid-in capital Additional Paid in Capital Financial Instruments [Domain] Financial Instruments [Domain] Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Depreciation Depreciation Options, exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Schedule of antidilutive securities excluded from computation of net loss per share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Commitments and Contingencies Commitments and Contingencies, Policy [Policy Text Block] Operating lease liabilities recognized for operating right-of-use assets Operating Lease Liabilities Recognized For Operating Lease Right-of-Use Assets Operating Lease Liabilities Recognized For Operating Lease Right-of-Use Assets Valuation Approach and Technique [Axis] Valuation Approach and Technique [Axis] Aggregate intrinsic value of options exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value Research and development contract costs Accrued Research And Contract Costs, Current Accrued Research And Contract Costs, Current Share-Based Payment Arrangement [Abstract] Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Cash and cash equivalents, beginning of period Cash and cash equivalents, end of period Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options Exercises And ESPP Purchases in Period Share-based Compensation Arrangement by Share-based Payment Award, Options Exercised And ESPP Purchased in Period Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Current liabilities: Liabilities, Current [Abstract] Common stock, shares issued (in shares) Common Stock, Shares, Issued Weighted average remaining contract life, vested and expected to vest Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term Net loss Net loss Net Income (Loss) Attributable to Parent Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive securities excluded from computation of net loss per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Unpaid amounts related to purchases of property and equipment Capital Expenditures Incurred but Not yet Paid Income Statement Location [Domain] Income Statement Location [Domain] Share-based payment award, grants in period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period Equity Component [Domain] Equity Component [Domain] Amendment Flag Amendment Flag Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Investments Investment, Policy [Policy Text Block] Exercise of stock options and purchases pursuant to employee stock purchase plan Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Accrued royalty Accrued Royalties Valuation Approach and Technique [Domain] Valuation Approach and Technique [Domain] Proceeds from the exercises of stock options and purchases pursuant to employee stock purchase plan Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Fair Value of Financial Instruments Fair Value Measurement, Policy [Policy Text Block] Plan Name [Axis] Plan Name [Axis] Entity Current Reporting Status Entity Current Reporting Status Other assets Other Assets, Noncurrent Total Fair Value Debt Securities, Available-for-Sale Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract] Options, exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Supplemental disclosures of non-cash financial activities: Supplemental Cash Flow Information [Abstract] Weighted average exercise price, forfeited (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price Impairment of long-lived assets Tangible Asset Impairment Charges Purchase price of common stock in percent Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent Unrecognized compensation cost for RSU Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Plan Name [Domain] Plan Name [Domain] Statement of Cash Flows [Abstract] Entity Address, State or Province Entity Address, State or Province Stock issued under ESPP (in shares) Stock Issued During Period, Shares, Employee Stock Purchase Plans ESPP Employee Stock [Member] Weighted average remaining contract life, outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term 2020 Stock Incentive Plan 2020 Stock Incentive Plan [Member] 2020 Stock Incentive Plan Options, beginning balance (in shares) Options, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Award Type [Axis] Award Type [Axis] Litigation settlement Estimated Litigation Liability, Current Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Basis of Presentation and Unaudited Interim Condensed Financial Statements Basis of Accounting, Policy [Policy Text Block] Property and equipment, net Property, Plant and Equipment, Net Schedule of investments Debt Securities, Available-for-Sale [Table Text Block] Investments: Debt Securities [Abstract] Stock options Share-Based Payment Arrangement, Option [Member] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Options, forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Other income (expense) Other Nonoperating Income (Expense) Common stock, shares authorized (in shares) Common Stock, Shares Authorized License agreement, maximum payment License Agreement, Royalty Payments, Maximum License Agreement, Royalty Payments, Maximum Schedule of Cash and Cash Equivalents [Table] Schedule of Cash and Cash Equivalents [Table] Total liabilities Liabilities Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Expense from operations Operating Expenses Cash flows from investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Deferred revenue Increase (Decrease) in Contract with Customer, Liability Total current assets Assets, Current Revenue Recognition Revenue from Contract with Customer [Policy Text Block] Investments Debt Securities, Available-for-Sale, Current Document Type Document Type Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Entity Small Business Entity Small Business Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Annual increase in number of shares authorized, term Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term Equity Stockholders' Equity Note Disclosure [Text Block] Non-cash operating lease expense Operating Lease, Right-of-Use Asset, Amortization Expense Debt securities, average maturity term Debt Securities, Available-for-Sale, Term Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Gross Unrealized Loss Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax Entity Shell Company Entity Shell Company Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Accrued expenses and other current liabilities Increase (Decrease) in Accrued Liabilities Aggregate intrinsic value of options outstanding Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Financial Instrument [Axis] Financial Instrument [Axis] Title of 12(b) Security Title of 12(b) Security Number of clinical-stage product candidate Number Of Clinical-stage Product Candidates Number Of Clinical-stage Product Candidates Document Period End Date Document Period End Date Payables and Accruals [Abstract] Net change in investments Payments for (Proceeds from) Available-for-Sale Securities, Short-Term Number of tranches Share-based Compensation Arrangement by Share-based Payment Award, Number Of Tranches Share-based Compensation Arrangement by Share-based Payment Award, Number Of Tranches Debt Securities, Available-for-sale [Table] Debt Securities, Available-for-Sale [Table] Total assets Assets Net amortization (accretion) of investments Accretion (Amortization) of Discounts and Premiums, Investments Investments, Debt and Equity Securities [Abstract] Income Statement Location [Axis] Income Statement Location [Axis] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Liabilities and Stockholders’ Equity Liabilities and Equity [Abstract] U.S. Treasury securities US Treasury Securities [Member] Weighted average exercise price, granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Amortized Cost Debt Securities, Available-for-Sale, Amortized Cost Weighted average exercise price, exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Litigation settlement, amount awarded to other party Litigation Settlement, Amount Awarded to Other Party Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Compensation and related benefits Employee-related Liabilities, Current Accounts payable Accounts Payable, Current Stockholders’ equity: Stockholders' Equity Attributable to Parent [Abstract] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Other assets Increase (Decrease) in Other Operating Assets Accrued expenses and other current liabilities Accrued expenses and other current liabilities Accrued Liabilities and Other Liabilities, Current Accrued Liabilities and Other Liabilities, Current Schedule of valuation assumptions Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Organization and Description of Business Nature of Operations [Text Block] Non-current operating lease liabilities Increase (Decrease) in Operating Lease Liability Entity Filer Category Entity Filer Category Weighted-average shares outstanding – basic (in shares) Weighted Average Number of Shares Outstanding, Basic Award Type [Domain] Award Type [Domain] Weighted-average amortization period Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Weighted average remaining contract life, exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Proceeds from ESPP Proceeds from Stock Plans Total stock-based compensation Share-Based Payment Arrangement, Expense Commitments and contingencies (Note 5) Commitments and Contingencies Common stock, additional capital shares reserved for future issuance (in shares) Common Stock, Additional Capital Shares Reserved for Future Issuance Common Stock, Additional Capital Shares Reserved for Future Issuance Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Weighted average exercise price, beginning balance (in dollars per share) Weighted average exercise price, ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Monte Carlo Option Pricing Model Monte Carlo Option Pricing Model [Member] Monte Carlo Option Pricing Model Expected dividends Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Unvested restricted stock Restricted Stock [Member] General and administrative General and Administrative Expense [Member] Collaboration revenue Revenue from Contract with Customer, Excluding Assessed Tax Entity Address, City or Town Entity Address, City or Town Shares reserved for future issuance Common Stock, Capital Shares Reserved for Future Issuance Operating expenses: Operating Expenses [Abstract] Cover [Abstract] Leases Lessee, Leases [Policy Text Block] Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Statement of Financial Position [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Black-Scholes Option Pricing Model Black-Scholes Option Pricing Model [Member] Black-Scholes Option Pricing Model Commitments and Contingencies Disclosure [Abstract] Taxes paid related to net share settlement of equity awards Payment, Tax Withholding, Share-Based Payment Arrangement Total liabilities and stockholders’ equity Liabilities and Equity Trading Symbol Trading Symbol Entity File Number Entity File Number Research and development Research and Development Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Restricted Stock Units (RSUs) Restricted Stock Units (RSUs) [Member] Current Fiscal Year End Date Current Fiscal Year End Date Accrued Expenses and Other Current Liabilities Accounts Payable and Accrued Liabilities Disclosure [Text Block] Net loss per share – diluted (in dollars per share) Earnings Per Share, Diluted Options, vested and expected to vest (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Use of Estimates Use of Estimates, Policy [Policy Text Block] Stock-based compensation, vesting period Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Accounts payable Increase (Decrease) in Accounts Payable Basis of Presentation and Summary of Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Total current liabilities Liabilities, Current Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Maximum value of shares per employee during any calendar year Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value Entity Ex Transition Period Entity Ex Transition Period Net loss per share – basic (in dollars per share) Earnings Per Share, Basic Share-based compensation, expiration period Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, Address Line One Entity Address, Address Line One Total stockholders’ equity Beginning balance Ending balance Stockholders' Equity Attributable to Parent Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Payments for royalties Payments for Royalties Entity Interactive Data Current Entity Interactive Data Current Deferred revenue billed but not received Revenue From Contract With Customer, Deferred Revenue Billed Not Received Revenue From Contract With Customer, Deferred Revenue Billed Not Received Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Schedule of accrued expenses and other current liabilities Schedule of Accrued Liabilities [Table Text Block] Money Market Funds Money Market Funds [Member] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Equity [Abstract] Accumulated Deficit Retained Earnings [Member] Unrecognized compensation cost Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Issuance of common stock upon settlement of restricted stock units (in shares) Awards, vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Cash and Cash Equivalents [Line Items] Cash and Cash Equivalents [Line Items] Entity Tax Identification Number Entity Tax Identification Number Common Stock Common Stock [Member] Contribution limit in percentage of employee's eligible compensation Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate Schedule of stock-based compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Statement [Table] Statement [Table] Cash, cash equivalents, and short-term investments Cash, Cash Equivalents, and Short-Term Investments Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Document Quarterly Report Document Quarterly Report Shares withheld related to net share settlement (in shares) Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation Current assets: Assets, Current [Abstract] Non-current operating lease liabilities Operating Lease, Liability, Noncurrent Net increase (decrease) in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Impairment of Long-Lived Assets Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block] Entity Central Index Key Entity Central Index Key Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Equity Components [Axis] Equity Components [Axis] Research and Development Costs Research and Development Expense, Policy [Policy Text Block] Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Threshold consecutive trading days Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Consecutive Trading Days Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Consecutive Trading Days Shares withheld related to net share settlement Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation Weighted average exercise price, exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Other Comprehensive Income (Loss) Comprehensive Income, Policy [Policy Text Block] Segment Information Segment Reporting, Policy [Policy Text Block] Concentration of Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Other current liabilities Other Accrued Liabilities, Current Document Fiscal Year Focus Document Fiscal Year Focus Cash flows from operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] City Area Code City Area Code Statement [Line Items] Statement [Line Items] General and administrative General and Administrative Expense Assets Assets [Abstract] Awards, beginning balance (in shares) Awards, ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Statement of Stockholders' Equity [Abstract] Cash flows from financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Accumulated Other Comprehensive Gain (Loss) AOCI Attributable to Parent [Member] Net Loss Per Share Earnings Per Share, Policy [Policy Text Block] Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Grant date fair value (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Weighted average exercise price, vested and expected to vest (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Document Transition Report Document Transition Report Local Phone Number Local Phone Number Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Schedule of option activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] Loss from operations Operating Income (Loss) Research and development Research and Development Expense [Member] Recently Adopted Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Operating right-of-use assets exchanged for operating lease liabilities Right-of-Use Asset Obtained in Exchange for Operating Lease Liability Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expense and Other Assets Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding License [Member] EX-101.PRE 9 sttk-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 10 R1.htm IDEA: XBRL DOCUMENT v3.23.1
COVER - shares
 3 Months Ended
Mar. 31, 2023
May 01, 2023
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2023  
Document Transition Report false  
Entity File Number 001-39593  
Entity Registrant Name Shattuck Labs, Inc.  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 81-2575858  
Entity Address, Address Line One 500 W. 5th Street  
Entity Address, Address Line Two Suite 1200  
Entity Address, City or Town Austin  
Entity Address, State or Province TX  
Entity Address, Postal Zip Code 78701  
City Area Code 512  
Local Phone Number 900-4690  
Title of 12(b) Security Common Stock, par value $0.0001 per share  
Trading Symbol STTK  
Security Exchange Name NASDAQ  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Non-accelerated Filer  
Entity Small Business true  
Entity Emerging Growth Company true  
Entity Ex Transition Period false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   42,471,288
Entity Central Index Key 0001680367  
Amendment Flag false  
Document Fiscal Year Focus 2023  
Document Fiscal Period Focus Q1  
Current Fiscal Year End Date --12-31  
XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED BALANCE SHEETS - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Current assets:    
Cash and cash equivalents $ 66,043 $ 47,379
Investments 69,452 113,901
Prepaid expenses and other current assets 22,342 23,304
Total current assets 157,837 184,584
Property and equipment, net 16,887 17,671
Other assets 2,953 3,069
Total assets 177,677 205,324
Current liabilities:    
Accounts payable 5,128 7,170
Accrued expenses and other current liabilities 10,881 17,795
Total current liabilities 16,009 24,965
Non-current operating lease liabilities 4,014 4,202
Total liabilities 20,023 29,167
Commitments and contingencies (Note 5)
Stockholders’ equity:    
Common stock, $0.0001 par value: 300,000,000 shares authorized; 42,460,258 shares issued and outstanding at March 31, 2023 and 42,390,586 shares issued and outstanding at December 31, 2022 5 5
Additional paid-in capital 397,724 396,041
Accumulated other comprehensive loss (339) (877)
Accumulated deficit (239,736) (219,012)
Total stockholders’ equity 157,654 176,157
Total liabilities and stockholders’ equity $ 177,677 $ 205,324
XML 12 R3.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED BALANCE SHEETS - Parenthetical - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Statement of Financial Position [Abstract]    
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized (in shares) 300,000,000 300,000,000
Common stock, shares issued (in shares) 42,460,258 42,390,586
Common stock, shares outstanding (in shares) 42,460,258 42,390,586
XML 13 R4.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Income Statement [Abstract]    
Revenue from Contract with Customer, Product and Service [Extensible List] License [Member] License [Member]
Collaboration revenue $ 57 $ 0
Operating expenses:    
Research and development 16,667 19,187
General and administrative 5,051 4,979
Expense from operations 21,718 24,166
Loss from operations (21,661) (24,166)
Other income (expense) 937 (362)
Net loss (20,724) (24,528)
Unrealized gain on investments 538 33
Comprehensive loss $ (20,186) $ (24,495)
Net loss per share – basic (in dollars per share) $ (0.49) $ (0.58)
Net loss per share – diluted (in dollars per share) $ (0.49) $ (0.58)
Weighted-average shares outstanding – basic (in shares) 42,439,204 42,357,625
Weighted-average shares outstanding – diluted (in shares) 42,439,204 42,357,625
XML 14 R5.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS’ EQUITY - USD ($)
$ in Thousands
Total
Common Stock
Additional Paid-In Capital
Accumulated Other Comprehensive Gain (Loss)
Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2021   42,338,898      
Beginning balance at Dec. 31, 2021 $ 271,786 $ 5 $ 389,408 $ (560) $ (117,067)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)   39,616      
Exercise of stock options and purchases pursuant to employee stock purchase plan 134   134    
Stock-based compensation expense 1,513   1,513    
Unrealized gain on investments 33     33  
Net loss (24,528)       (24,528)
Ending balance (in shares) at Mar. 31, 2022   42,378,514      
Ending balance at Mar. 31, 2022 248,938 $ 5 391,055 (527) (141,595)
Beginning balance (in shares) at Dec. 31, 2022   42,390,586      
Beginning balance at Dec. 31, 2022 176,157 $ 5 396,041 (877) (219,012)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)   11,888      
Exercise of stock options and purchases pursuant to employee stock purchase plan $ 39   39    
Issuance of common stock upon settlement of restricted stock units (in shares)   73,937      
Shares withheld related to net share settlement (in shares) (16,153)        
Shares withheld related to net share settlement $ (39)   (39)    
Stock-based compensation expense 1,683   1,683    
Unrealized gain on investments 538     538  
Net loss (20,724)       (20,724)
Ending balance (in shares) at Mar. 31, 2023   42,460,258      
Ending balance at Mar. 31, 2023 $ 157,654 $ 5 $ 397,724 $ (339) $ (239,736)
XML 15 R6.htm IDEA: XBRL DOCUMENT v3.23.1
CONDENSED STATEMENTS OF CASH FLOWS - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Cash flows from operating activities:    
Net loss $ (20,724) $ (24,528)
Adjustments to reconcile net loss to net cash used in operations:    
Stock-based compensation 1,683 1,513
Depreciation 1,014 472
Non-cash operating lease expense 85 65
Net amortization (accretion) of investments (213) 981
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 1,462 3,699
Other assets 30 25
Accounts payable (2,197) (7,738)
Accrued expenses and other current liabilities (7,356) (601)
Non-current operating lease liabilities (188) (165)
Deferred revenue (57) 0
Net cash used in operating activities (26,461) (26,277)
Cash flows from investing activities:    
Purchases of property and equipment (75) (2,488)
Net change in investments 45,200 (12,894)
Net cash provided by (used in) investing activities 45,125 (15,382)
Cash flows from financing activities:    
Proceeds from the exercises of stock options and purchases pursuant to employee stock purchase plan 39 134
Taxes paid related to net share settlement of equity awards (39) 0
Net cash provided by financing activities 0 134
Net increase (decrease) in cash and cash equivalents 18,664 (41,525)
Cash and cash equivalents, beginning of period 47,379 92,268
Cash and cash equivalents, end of period 66,043 50,743
Supplemental disclosures of non-cash financial activities:    
Operating lease liabilities recognized for operating right-of-use assets 0 5,447
Operating right-of-use assets exchanged for operating lease liabilities 0 2,945
Deferred revenue billed but not received 500 0
Unpaid amounts related to purchases of property and equipment $ 155 $ 319
XML 16 R7.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and Description of Business
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Organization and Description of Business Organization and Description of Business
Shattuck Labs, Inc. (the “Company”) was incorporated in 2016 in the State of Delaware and is a clinical-stage biopharmaceutical company developing dual-sided fusion proteins, including its Agonist Redirected Checkpoint (“ARC®”) and gamma delta T cell engager (“GADLEN™”) platforms, as novel classes of biologic medicines capable of multifunctional activity with potential applications in oncology and inflammatory diseases. Using its proprietary technology, the Company is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. The Company has one clinical-stage product candidate, SL-172154, and has several compounds in preclinical development.
Liquidity
The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $239.7 million as of March 31, 2023. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company’s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company’s cash and cash equivalents and investments of $135.5 million as of March 31, 2023 are sufficient to fund projected operations of the Company for at least the next twelve months.
Global Economic Considerations
In addition, the global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine and other political tensions, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on our future operations.
XML 17 R8.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation and Summary of Significant Accounting Policies
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Summary of Significant Accounting Policies
Basis of Presentation
The accompanying unaudited interim condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).
Unaudited Interim Condensed Financial Statements
In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position, its results of operations, statements of changes in stockholders’ equity and cash flows for the interim periods presented. Operating results for interim periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The interim financial statements presented herein do not contain all required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed financial statements should be read in conjunction with the annual audited financial statements and related notes in our Annual Report on Form 10-K for the year ended December 31, 2022.
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition,
the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management’s estimates.
Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one segment.
Fair Value of Financial Instruments
Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories:
•Level 1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date;
•Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
•Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Management believes that the carrying amounts of the Company’s financial instruments, including investments and accounts payable, approximate fair value due to the short-term nature of those instruments.
Concentration of Risk
Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. While the Company has not experienced any losses, the recent failure of Silicon Valley Bank (“SVB”), at which the Company held cash, exposed the Company to significant credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors. The Company is in the process of transferring its cash to an alternate depository institution, the financial position of which management believes does not expose the Company to significant credit risk. Where possible, the Company will also continue to hold its excess cash in investments and money market accounts to further limit exposure. The Company does not believe that it is subject to other unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value.
The Company is highly dependent on a limited number of contract manufacturing organizations (“CMOs”) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products.
The Company is highly dependent on a limited number of contract research organizations (“CROs”) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.
Cash and Cash Equivalents
The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents consisted of $0.8 million held in operating accounts and $65.2 million held in money market funds as of March 31, 2023, and $3.5 million held in operating accounts and $43.9 million held in money market funds as of December 31, 2022.
Investments
The Company’s investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income (loss), a component of stockholders’ equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. As of March 31, 2023 and December 31, 2022, there were no impairments related to credit losses of investments.
Impairment of Long-Lived Assets
Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were no impairments of long-lived assets for the three months ended March 31, 2023 and 2022.
Leases
The Company determines if an arrangement is a lease at inception. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The classification of the Company’s leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company’s operating leases is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirement of Accounting Standards Codification (“ASC”) 842, Leases of the Financial Accounting Standards Board (“FASB”) to leases with a term of 12 months or less for all classes of assets.
Commitments and Contingencies
The Company follows ASC 450-20, Contingencies of the FASB to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims
that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.
If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.
Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.
Revenue Recognition
Collaboration revenue is recognized in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.
Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below.
When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method.
The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed:
i.identify the contract(s) with a customer;
ii.identify the performance obligations in the contract;
iii.determine the transaction price;
iv.allocate the transaction price to the performance obligations within the contract; and
v.recognize revenue when (or as) the entity satisfies a performance obligation.
The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.
At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company’s arrangements may consist of a license of, or options to license, the Company’s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the
customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources and (ii) are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.
The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.
The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.
Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company’s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities.
The Company’s collaboration revenue arrangements may include the following:
Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances.
Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will
recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).
To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales.
Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, Research and Development. The Company considered the guidance in ASC 808, Collaborative Arrangements and will recognize the payments received from these agreements as revenue when the related costs are incurred.
Research and Development Costs
Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities.
A substantial portion of the Company’s ongoing research and development activities are conducted by third-party service providers, including CROs and CMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO or outside service provider, the payments will be recorded as a prepaid asset, which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company’s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company’s accruals that could materially affect the Company’s results of operations.
Net Loss Per Share
Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock or convertible notes, if any, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.
The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of March 31, 2023 and 2022, as they would be anti-dilutive:
Three Months Ended March 31,
20232022
Stock options5,261,439 3,460,911 
Unvested restricted stock652,598 313,390 
5,914,037 3,774,301 
Other Comprehensive Income (Loss)
Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on investments.
Recently Adopted Accounting Pronouncements
None.
XML 18 R9.htm IDEA: XBRL DOCUMENT v3.23.1
Investments
 3 Months Ended
Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]  
Investments Investments
The following table represents the Company’s available for sale investments by major security type (amounts in thousands):
March 31, 2023
Amortized
Cost		Gross Unrealized LossTotal Fair Value
Investments:
U.S. Treasury securities$69,791 $(339)$69,452 
Total investments$69,791 $(339)$69,452 
December 31, 2022
Amortized
Cost		Gross Unrealized LossTotal Fair Value
Investments:
U.S. Treasury securities$114,778 $(877)$113,901 
Total investments$114,778 $(877)$113,901 
 
The Company’s investment instruments and cash and cash equivalents are classified using Level 1 inputs within the fair value hierarchy and are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Debt securities have a weighted-average maturity of 0.24 years as of March 31, 2023.
XML 19 R10.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued Expenses and Other Current Liabilities
 3 Months Ended
Mar. 31, 2023
Payables and Accruals [Abstract]  
Accrued Expenses and Other Current Liabilities Accrued Expenses and Other Current Liabilities
Accrued expenses and other current liabilities consisted of the following (amounts in thousands):
March 31,
2023		December 31,
2022
Research and development contract costs$6,650 $11,256 
Litigation settlement1,400 1,400 
Compensation and related benefits1,203 3,967 
Other current liabilities1,628 1,172 
Total accrued expenses and other current liabilities$10,881 $17,795 
XML 20 R11.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies
 3 Months Ended
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]  
Commitments and Contingencies Commitments and Contingencies
Operating Leases
The Company leases certain office space, laboratory facilities, and equipment. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has operating leases. There have been no material changes in our operating leases as compared to operating leases disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022.
Nighthawk Biosciences, Inc. License Agreement
In connection with a license agreement with Nighthawk Biosciences, Inc. (“Nighthawk”), the Company is required to make payments of up to $20.6 million in aggregate for the achievement of specified development, regulatory and commercial sales milestones for certain licensed products. The Company paid $0.1 million to Nighthawk in the three months ended March 31, 2023 as a milestone payment for the Company’s completion of a Phase 1 clinical trial for SL-172154. The Company is required to pay Nighthawk a percentage of upfront fees or other non-royalty payments not tied to milestone events that it receives in connection with certain sublicenses of the licensed patents. The Company is also required to pay Nighthawk a royalty on all of its worldwide net sales, those of its affiliates, and sublicenses of certain licensed patents in the low single digits. The Company has not recorded a liability for the aforementioned payments given the achievement of specified development, regulatory and commercial sales milestones for certain licensed products is not probable as of the balance sheet date.
Litigation
From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. On January 31, 2022 and February 11, 2022, putative class action lawsuits were filed in the U.S. District Court for the Eastern District of New York against us and certain of the Company’s officers and directors. The cases were consolidated on June 2, 2022, and the plaintiffs filed an amended complaint on July 1, 2022. The amended complaint cites the volatility in the Company’s common stock and alleges that the defendants made or are responsible for misleading omissions regarding the Company’s clinical trial results and the collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company, Ltd. The parties reached a settlement in principle of the plaintiffs’ claims in the amount of $1.4 million on November 2, 2022. The settlement is subject to a definitive settlement agreement, notice to stockholders and court approval. The parties filed their motion for preliminary approval of the settlement agreement with the court on December 14, 2022, and, as of May 8, 2023, that motion is pending. The Company has accrued the settlement amount in accrued expenses and other current liabilities as of March 31, 2023.
Contractual Obligations
Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company’s contractual obligations result primarily from obligations for various CMOs and CROs, which include potential payments that may be required under its agreements. The contracts also contain variable costs and milestones that are hard to predict, as they are based on such things as patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under CMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Such agreements are cancellable upon written notice by the Company and, therefore, are not long-term liabilities.
XML 21 R12.htm IDEA: XBRL DOCUMENT v3.23.1
Equity
 3 Months Ended
Mar. 31, 2023
Equity [Abstract]  
Equity EquityThe Company is authorized to issue up to 300,000,000 shares of common stock and 10,000,000 shares of preferred stock, all with a par value of $0.0001 per share. The holders of the Company’s common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. The Company’s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of the Company’s common stock will receive ratably any dividends declared by the Company’s board of directors (“Board”) out of funds legally available. In the event of the Company’s liquidation, dissolution or winding-up, the holders of the Company’s common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. As of the periods presented, no common stock dividends had been declared by the Board. At March 31, 2023, none of the 10,000,000 shares of preferred stock were outstanding, and the Company has no present plans to issue any shares of preferred stock.
XML 22 R13.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Stock-Based Compensation Stock-Based Compensation
2020 Equity Incentive Plan
In September 2020, the Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”) which, as of the adoption date, replaced the 2016 Stock Incentive Plan. Under the 2020 Plan, the share reserve automatically
increases on January 1st of each year beginning in 2021 and ending with a final increase on January 1, 2030 in an amount equal to 4% of the Company’s outstanding common shares on December 31st of the preceding calendar year. The Board may provide that there will be no increase in the share reserve for any such year or that the increase in the share reserve may be smaller than would otherwise occur. On January 1, 2023, the share reserve automatically increased by 1,695,623 shares. As of March 31, 2023, there were 3,739,124 shares available for future grants. The 2020 Plan permits the granting of options, stock appreciation rights, restricted stock units (“RSUs”), performance stock and performance cash awards. The terms of the agreements under the 2020 Plan are determined by the Board. The Company’s awards generally vest over four years and have a term of 10 years. In 2023, the Company granted 165,050 awards that vest in three equal tranches based on the Company achieving a certain closing share price for each tranche for 30 consecutive trading days on or before the fourth anniversary of the grant date.
2020 Employee Stock Purchase Plan
The 2020 Employee Stock Purchase Plan (“2020 ESPP”) became effective in October 2020. A total of 395,795 shares of common stock were reserved for issuance under the 2020 ESPP. Eligible employees may purchase shares of common stock under the 2020 ESPP at 85% of the lower of the fair market value of the Company’s common stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee’s eligible compensation and may not purchase more than $25,000 of stock during any calendar year or more than 600 shares during any one purchase period. The 2020 ESPP share reserve automatically increases on January 1st of each calendar year, for ten years, commencing on January 1, 2021, in an amount equal to 1% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Board may act prior to January 1st of a given year to provide that there will be no January 1st increase of the share reserve for such year or that the increase in the share reserve for such year will be a smaller number of shares of common stock than would otherwise occur pursuant to the preceding sentence. On January 1, 2023, the share reserve increased by 423,905 shares. As of March 31, 2023, there were 1,216,723 shares available for future grants. During the three months ended March 31, 2023 and 2022, the Company issued 11,171 and 5,227 shares of common stock for aggregate cash proceeds of $0.1 million and $0.1 million, respectively.
The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim condensed statements of operations and comprehensive loss (in thousands):
Three Months Ended March 31,
20232022
Research and development$814 $827 
General and administrative869 686 
Total stock-based compensation$1,683 $1,513 
The following table summarizes option activity under the 2020 Plan:
Options
Weighted
Average
Exercise Price
Weighted
Average
Remaining Life
(Years)
Balance at December 31, 20224,209,255 $8.29 8.07
Granted1,181,087 3.57 
Exercised(717)2.95 
Forfeited(128,186)7.57 
Balance at March 31, 20235,261,439 $7.25 8.07
Vested and expected to vest5,174,691 $7.27 8.05
Exercisable at the end of the period2,122,655 $8.28 6.55
Options granted during the three months ended March 31, 2023 and 2022 had weighted-average grant-date fair values of $2.46 and $5.13 per share, respectively. As of March 31, 2023, the unrecognized compensation cost for options issued was $14.1 million and will be recognized over an estimated weighted-average amortization period of 2.49 years. The total intrinsic value of options exercised during the three months ended March 31, 2023 and 2022
was $0.1 million and $0.1 million, respectively. The aggregate intrinsic value of options outstanding and exercisable as of March 31, 2023 was $0.2 million.
Restricted Stock Units
The following table summarizes employee RSU activity for the three months ended March 31, 2023:
Awards
Weighted
Average
Grant Date Fair Value
Unvested RSUs as of December 31, 2022309,477 $7.22 
Granted445,025 3.57 
Released(73,937)7.43 
Forfeited(27,967)4.89 
Balance at March 31, 2023
652,598 $4.81 
The Company recognized $0.2 million of stock-based compensation related to RSUs as of March 31, 2023. As of March 31, 2023, the unrecognized compensation cost for RSUs issued was $3.1 million and will be recognized over an estimated weighted-average amortization period of 3.47 years. The fair values of RSUs are based on the fair value of the Company’s common stock on the date of the grant.
Fair Value of Stock Options and Shares Issued
The Company accounts for stock-based compensation by measuring and recognizing as compensation expense the fair value of all share-based payment awards made to employees, including employee stock options and restricted stock awards. The Company uses the Black-Scholes option pricing model to estimate the fair value of employee stock options that only have service or performance conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The inputs to both pricing models require a number of management estimates such as the expected term, volatility, risk-free interest rate and dividend yield. The fair value of stock options was determined using the methods and assumptions discussed below.
•The expected term of employee stock options with service-based vesting is determined using the “simplified” method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company’s lack of sufficient historical data.
•The expected stock price volatility assumption is based on the historical volatilities of the common stock of a peer group of publicly traded companies as well as the historical volatility of the Company’s common stock since the Company began trading subsequent to the Company’s initial public offering (“IPO”) in October 2020 over the period corresponding to the expected life as of the grant date. The historical volatility data was computed using the daily closing prices during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company’s stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. In the latter case, other suitable, similar entities whose share prices are publicly available would be utilized in the calculation.
•The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term.
•The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay dividends on its common stock.
•Prior to the Company’s IPO, the Board periodically estimated the fair value of the Company’s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. Subsequent to the Company’s IPO, options are issued with a strike price no less than the market price on date of grant.
The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company’s 2020 Plan were estimated using the following weighted-average assumptions:
Three Months Ended March 31,
20232022
2020 Plan
Expected term - years6.086.08
Expected volatility84.8%81.9%
Risk-free interest rate3.5%1.6%
Expected dividends——
The grant-date fair value of options calculated using the Monte Carlo option pricing model granted under the Company’s 2020 Plan were estimated using the following assumptions:
Three Months Ended March 31,
20232022
2020 Plan
Expected term - years4.004.00
Expected volatility80.0%80.0%
Risk-free interest rate3.6%1.4%
Expected dividends——
The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company’s 2020 ESPP were estimated using the following weighted-average assumptions:
Three Months Ended March 31,
20232022
2020 ESPP
Expected term - years0.490.49
Expected volatility84.8%81.8%
Risk-free interest rate3.5%2.0%
Expected dividends——
XML 23 R14.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation and Summary of Significant Accounting Policies (Policies)
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Basis of Presentation and Unaudited Interim Condensed Financial Statements
Basis of Presentation
The accompanying unaudited interim condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).
Unaudited Interim Condensed Financial Statements
In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position, its results of operations, statements of changes in stockholders’ equity and cash flows for the interim periods presented. Operating results for interim periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The interim financial statements presented herein do not contain all required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed financial statements should be read in conjunction with the annual audited financial statements and related notes in our Annual Report on Form 10-K for the year ended December 31, 2022.
Use of Estimates
Use of Estimates
The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition,
the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management’s estimates.
Segment Information
Segment Information
Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one segment.
Fair Value of Financial Instruments
Fair Value of Financial Instruments
Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories:
•Level 1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date;
•Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and
•Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions.
Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis.
Management believes that the carrying amounts of the Company’s financial instruments, including investments and accounts payable, approximate fair value due to the short-term nature of those instruments.
Concentration of Risk
Concentration of Risk
Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. While the Company has not experienced any losses, the recent failure of Silicon Valley Bank (“SVB”), at which the Company held cash, exposed the Company to significant credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors. The Company is in the process of transferring its cash to an alternate depository institution, the financial position of which management believes does not expose the Company to significant credit risk. Where possible, the Company will also continue to hold its excess cash in investments and money market accounts to further limit exposure. The Company does not believe that it is subject to other unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value.
The Company is highly dependent on a limited number of contract manufacturing organizations (“CMOs”) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products.
The Company is highly dependent on a limited number of contract research organizations (“CROs”) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties.
Cash and Cash Equivalents Cash and Cash Equivalents The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents.
Investments Investments The Company’s investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income (loss), a component of stockholders’ equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter.
Impairment of Long-Lived Assets Impairment of Long-Lived AssetsLong-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets.
Leases
Leases
The Company determines if an arrangement is a lease at inception. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The classification of the Company’s leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company’s operating leases is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirement of Accounting Standards Codification (“ASC”) 842, Leases of the Financial Accounting Standards Board (“FASB”) to leases with a term of 12 months or less for all classes of assets.
Commitments and Contingencies
Commitments and Contingencies
The Company follows ASC 450-20, Contingencies of the FASB to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims
that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.
If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.
Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.
Revenue Recognition
Revenue Recognition
Collaboration revenue is recognized in accordance with ASC 606, Revenue from Contracts with Customers (“ASC 606”). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract.
Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below.
When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method.
The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed:
i.identify the contract(s) with a customer;
ii.identify the performance obligations in the contract;
iii.determine the transaction price;
iv.allocate the transaction price to the performance obligations within the contract; and
v.recognize revenue when (or as) the entity satisfies a performance obligation.
The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.
At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company’s arrangements may consist of a license of, or options to license, the Company’s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the
customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources and (ii) are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation.
The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.
The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue.
Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company’s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities.
The Company’s collaboration revenue arrangements may include the following:
Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition.
Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances.
Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will
recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).
To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales.
Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, Research and Development. The Company considered the guidance in ASC 808, Collaborative Arrangements and will recognize the payments received from these agreements as revenue when the related costs are incurred.
Research and Development Costs
Research and Development Costs
Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities.
A substantial portion of the Company’s ongoing research and development activities are conducted by third-party service providers, including CROs and CMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO or outside service provider, the payments will be recorded as a prepaid asset, which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company’s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company’s accruals that could materially affect the Company’s results of operations.
Net Loss Per Share Net Loss Per Share Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock or convertible notes, if any, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive.
Other Comprehensive Income (Loss) Other Comprehensive Income (Loss) Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on investments.
Recently Adopted Accounting Pronouncements
Recently Adopted Accounting Pronouncements
None.
XML 24 R15.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation and Summary of Significant Accounting Policies (Tables)
 3 Months Ended
Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]  
Schedule of antidilutive securities excluded from computation of net loss per share The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of March 31, 2023 and 2022, as they would be anti-dilutive:
Three Months Ended March 31,
20232022
Stock options5,261,439 3,460,911 
Unvested restricted stock652,598 313,390 
5,914,037 3,774,301 
XML 25 R16.htm IDEA: XBRL DOCUMENT v3.23.1
Investments (Tables)
 3 Months Ended
Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]  
Schedule of investments
The following table represents the Company’s available for sale investments by major security type (amounts in thousands):
March 31, 2023
Amortized
Cost		Gross Unrealized LossTotal Fair Value
Investments:
U.S. Treasury securities$69,791 $(339)$69,452 
Total investments$69,791 $(339)$69,452 
December 31, 2022
Amortized
Cost		Gross Unrealized LossTotal Fair Value
Investments:
U.S. Treasury securities$114,778 $(877)$113,901 
Total investments$114,778 $(877)$113,901 
XML 26 R17.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued Expenses and Other Current Liabilities (Tables)
 3 Months Ended
Mar. 31, 2023
Payables and Accruals [Abstract]  
Schedule of accrued expenses and other current liabilities
Accrued expenses and other current liabilities consisted of the following (amounts in thousands):
March 31,
2023		December 31,
2022
Research and development contract costs$6,650 $11,256 
Litigation settlement1,400 1,400 
Compensation and related benefits1,203 3,967 
Other current liabilities1,628 1,172 
Total accrued expenses and other current liabilities$10,881 $17,795 
XML 27 R18.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]  
Schedule of stock-based compensation expense
The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim condensed statements of operations and comprehensive loss (in thousands):
Three Months Ended March 31,
20232022
Research and development$814 $827 
General and administrative869 686 
Total stock-based compensation$1,683 $1,513 
Schedule of option activity
The following table summarizes option activity under the 2020 Plan:
Options
Weighted
Average
Exercise Price
Weighted
Average
Remaining Life
(Years)
Balance at December 31, 20224,209,255 $8.29 8.07
Granted1,181,087 3.57 
Exercised(717)2.95 
Forfeited(128,186)7.57 
Balance at March 31, 20235,261,439 $7.25 8.07
Vested and expected to vest5,174,691 $7.27 8.05
Exercisable at the end of the period2,122,655 $8.28 6.55
Schedule of RSU activity
The following table summarizes employee RSU activity for the three months ended March 31, 2023:
Awards
Weighted
Average
Grant Date Fair Value
Unvested RSUs as of December 31, 2022309,477 $7.22 
Granted445,025 3.57 
Released(73,937)7.43 
Forfeited(27,967)4.89 
Balance at March 31, 2023
652,598 $4.81 
Schedule of valuation assumptions
The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company’s 2020 Plan were estimated using the following weighted-average assumptions:
Three Months Ended March 31,
20232022
2020 Plan
Expected term - years6.086.08
Expected volatility84.8%81.9%
Risk-free interest rate3.5%1.6%
Expected dividends——
The grant-date fair value of options calculated using the Monte Carlo option pricing model granted under the Company’s 2020 Plan were estimated using the following assumptions:
Three Months Ended March 31,
20232022
2020 Plan
Expected term - years4.004.00
Expected volatility80.0%80.0%
Risk-free interest rate3.6%1.4%
Expected dividends——
The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company’s 2020 ESPP were estimated using the following weighted-average assumptions:
Three Months Ended March 31,
20232022
2020 ESPP
Expected term - years0.490.49
Expected volatility84.8%81.8%
Risk-free interest rate3.5%2.0%
Expected dividends——
XML 28 R19.htm IDEA: XBRL DOCUMENT v3.23.1
Organization and Description of Business (Details)
$ in Thousands
Mar. 31, 2023
USD ($)
candidate
Dec. 31, 2022
USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]    
Number of clinical-stage product candidate | candidate 1  
Accumulated deficit $ 239,736 $ 219,012
Cash, cash equivalents, and short-term investments $ 135,500  
XML 29 R20.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Dec. 31, 2022
Cash and Cash Equivalents [Line Items]      
Cash and cash equivalents $ 66,043   $ 47,379
Impairment of long-lived assets 0 $ 0  
Operating Account      
Cash and Cash Equivalents [Line Items]      
Cash and cash equivalents 800   3,500
Money Market Funds      
Cash and Cash Equivalents [Line Items]      
Cash and cash equivalents $ 65,200   $ 43,900
XML 30 R21.htm IDEA: XBRL DOCUMENT v3.23.1
Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details) - shares
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of net loss per share (in shares) 5,914,037 3,774,301
Stock options    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of net loss per share (in shares) 5,261,439 3,460,911
Unvested restricted stock    
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]    
Antidilutive securities excluded from computation of net loss per share (in shares) 652,598 313,390
XML 31 R22.htm IDEA: XBRL DOCUMENT v3.23.1
Investments - Schedule of available for sale investments (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Investments:    
Amortized Cost $ 69,791 $ 114,778
Gross Unrealized Loss (339) (877)
Total Fair Value 69,452 113,901
U.S. Treasury securities    
Investments:    
Amortized Cost 69,791 114,778
Gross Unrealized Loss (339) (877)
Total Fair Value $ 69,452 $ 113,901
XML 32 R23.htm IDEA: XBRL DOCUMENT v3.23.1
Investments - Narrative (Details)
Mar. 31, 2023
Investments, Debt and Equity Securities [Abstract]  
Debt securities, average maturity term 2 months 26 days
XML 33 R24.htm IDEA: XBRL DOCUMENT v3.23.1
Accrued Expenses and Other Current Liabilities - Schedule of accrued expenses and other current liabilities (Details) - USD ($)
$ in Thousands
Mar. 31, 2023
Dec. 31, 2022
Payables and Accruals [Abstract]    
Research and development contract costs $ 6,650 $ 11,256
Litigation settlement 1,400 1,400
Compensation and related benefits 1,203 3,967
Other current liabilities 1,628 1,172
Accrued expenses and other current liabilities $ 10,881 $ 17,795
XML 34 R25.htm IDEA: XBRL DOCUMENT v3.23.1
Commitments and Contingencies - Narrative (Details) - USD ($)
 3 Months Ended
Nov. 02, 2022
Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]    
License agreement, maximum payment   $ 20,600,000
Payments for royalties   100,000
Accrued royalty   $ 0
Litigation settlement, amount awarded to other party $ 1,400,000  
XML 35 R26.htm IDEA: XBRL DOCUMENT v3.23.1
Equity (Details) - $ / shares
Mar. 31, 2023
Dec. 31, 2022
Equity [Abstract]    
Common stock, shares authorized (in shares) 300,000,000 300,000,000
Preferred stock, shares authorized (in shares) 10,000,000  
Common stock, par value (in dollars per share) $ 0.0001 $ 0.0001
Preferred stock, par value (in dollars per share) $ 0.0001  
Preferred stock, shares outstanding (in shares) 0  
XML 36 R27.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Narrative (Details)
$ / shares in Units, $ in Thousands
 3 Months Ended
Jan. 01, 2023
shares
Jan. 01, 2021
Oct. 14, 2020
USD ($)
shares
Mar. 31, 2023
USD ($)
tranch
$ / shares
shares
Mar. 31, 2022
USD ($)
$ / shares
shares
Sep. 30, 2020
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Grant date fair value (in dollars per share) | $ / shares       $ 2.46 $ 5.13  
Unrecognized compensation cost       $ 14,100    
Intrinsic value of options exercised       100 $ 100  
Aggregate intrinsic value of options exercisable       200    
Aggregate intrinsic value of options outstanding       200    
Total stock-based compensation       $ 1,683 $ 1,513  
Stock options            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Weighted-average amortization period       2 years 5 months 26 days    
Expected dividends       0.00%    
Restricted Stock Units (RSUs)            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Weighted-average amortization period       3 years 5 months 19 days    
Total stock-based compensation       $ 200    
Unrecognized compensation cost for RSU       $ 3,100    
2020 Stock Incentive Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Increase in number of shares authorized, percentage of capital stock outstanding           0.04
Common stock, additional capital shares reserved for future issuance (in shares) | shares 1,695,623          
Shares reserved for future issuance | shares       3,739,124    
Stock-based compensation, vesting period       4 years    
Share-based compensation, expiration period       10 years    
Share-based payment award, grants in period (in shares) | shares       165,050    
Number of tranches | tranch       3    
Threshold consecutive trading days       30 days    
2020 Employee Stock Purchase Plan            
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]            
Increase in number of shares authorized, percentage of capital stock outstanding     0.01      
Common stock, additional capital shares reserved for future issuance (in shares) | shares 423,905          
Shares reserved for future issuance | shares     395,795 1,216,723    
Purchase price of common stock in percent     85.00%      
Contribution limit in percentage of employee's eligible compensation     15.00%      
Maximum value of shares per employee during any calendar year     $ 25      
Maximum number of shares per employee during any one purchase period (in shares) | shares     600      
Annual increase in number of shares authorized, term   10 years        
Stock issued under ESPP (in shares) | shares       11,171 5,227  
Proceeds from ESPP       $ 100 $ 100  
XML 37 R28.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Schedule of stock-based compensation expense (Details) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation $ 1,683 $ 1,513
Research and development    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation 814 827
General and administrative    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Total stock-based compensation $ 869 $ 686
XML 38 R29.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Schedule of option activity (Details) - $ / shares
 3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2022
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]    
Options, beginning balance (in shares) 4,209,255  
Options, granted (in shares) 1,181,087  
Options, exercised (in shares) (717)  
Options, forfeited (in shares) (128,186)  
Options, ending balance (in shares) 5,261,439 4,209,255
Options, vested and expected to vest (in shares) 5,174,691  
Options, exercisable (in shares) 2,122,655  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]    
Weighted average exercise price, beginning balance (in dollars per share) $ 8.29  
Weighted average exercise price, granted (in dollars per share) 3.57  
Weighted average exercise price, exercised (in dollars per share) 2.95  
Weighted average exercise price, forfeited (in dollars per share) 7.57  
Weighted average exercise price, ending balance (in dollars per share) 7.25 $ 8.29
Weighted average exercise price, vested and expected to vest (in dollars per share) 7.27  
Weighted average exercise price, exercisable (in dollars per share) $ 8.28  
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]    
Weighted average remaining contract life, outstanding 8 years 25 days 8 years 25 days
Weighted average remaining contract life, vested and expected to vest 8 years 18 days  
Weighted average remaining contract life, exercisable 6 years 6 months 18 days  
XML 39 R30.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Schedule of restricted stock activity (Details) - Restricted Stock Units (RSUs)
 3 Months Ended
Mar. 31, 2023
$ / shares
shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]  
Awards, beginning balance (in shares) | shares 309,477
Granted (in shares) | shares 445,025
Awards, vested (in shares) | shares (73,937)
Forfeited (in shares) | shares (27,967)
Awards, ending balance (in shares) | shares 652,598
Weighted Average Grant Date Fair Value  
Beginning balance (in dollars per share) | $ / shares $ 7.22
Granted (in dollars per share) | $ / shares 3.57
Vested (in dollars per share) | $ / shares 7.43
Forfeited (in dollars per share) | $ / shares 4.89
Ending balance (in dollars per share) | $ / shares $ 4.81
XML 40 R31.htm IDEA: XBRL DOCUMENT v3.23.1
Stock-Based Compensation - Schedule of valuation assumptions (Details)
 3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Stock options    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected dividends 0.00%  
Stock options | 2020 Stock Incentive Plan | Black-Scholes Option Pricing Model    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term - years 6 years 29 days 6 years 29 days
Expected volatility 84.80% 81.90%
Risk-free interest rate 3.50% 1.60%
Expected dividends 0.00% 0.00%
Stock options | 2020 Stock Incentive Plan | Monte Carlo Option Pricing Model    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term - years 4 years 4 years
Expected volatility 80.00% 80.00%
Risk-free interest rate 3.60% 1.40%
Expected dividends 0.00% 0.00%
ESPP | 2020 Employee Stock Purchase Plan | Black-Scholes Option Pricing Model    
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]    
Expected term - years 5 months 26 days 5 months 26 days
Expected volatility 84.80% 81.80%
Risk-free interest rate 3.50% 2.00%
Expected dividends 0.00% 0.00%
XML 41 sttk-20230331_htm.xml IDEA: XBRL DOCUMENT 0001680367 2023-01-01 2023-03-31 0001680367 2023-05-01 0001680367 2023-03-31 0001680367 2022-12-31 0001680367 2022-01-01 2022-03-31 0001680367 us-gaap:CommonStockMember 2022-12-31 0001680367 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001680367 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001680367 us-gaap:RetainedEarningsMember 2022-12-31 0001680367 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001680367 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001680367 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001680367 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001680367 us-gaap:CommonStockMember 2023-03-31 0001680367 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001680367 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001680367 us-gaap:RetainedEarningsMember 2023-03-31 0001680367 us-gaap:CommonStockMember 2021-12-31 0001680367 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001680367 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001680367 us-gaap:RetainedEarningsMember 2021-12-31 0001680367 2021-12-31 0001680367 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001680367 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001680367 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001680367 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001680367 us-gaap:CommonStockMember 2022-03-31 0001680367 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001680367 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001680367 us-gaap:RetainedEarningsMember 2022-03-31 0001680367 2022-03-31 0001680367 sttk:OperatingAccountMember 2023-03-31 0001680367 us-gaap:MoneyMarketFundsMember 2023-03-31 0001680367 sttk:OperatingAccountMember 2022-12-31 0001680367 us-gaap:MoneyMarketFundsMember 2022-12-31 0001680367 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001680367 us-gaap:EmployeeStockOptionMember 2022-01-01 2022-03-31 0001680367 us-gaap:RestrictedStockMember 2023-01-01 2023-03-31 0001680367 us-gaap:RestrictedStockMember 2022-01-01 2022-03-31 0001680367 us-gaap:USTreasurySecuritiesMember 2023-03-31 0001680367 us-gaap:USTreasurySecuritiesMember 2022-12-31 0001680367 2022-11-02 2022-11-02 0001680367 sttk:A2020StockIncentivePlanMember 2020-09-30 0001680367 sttk:A2020StockIncentivePlanMember 2023-01-01 2023-01-01 0001680367 sttk:A2020StockIncentivePlanMember 2023-03-31 0001680367 sttk:A2020StockIncentivePlanMember 2023-01-01 2023-03-31 0001680367 sttk:A2020EmployeeStockPurchasePlanMember 2020-10-14 0001680367 sttk:A2020EmployeeStockPurchasePlanMember 2020-10-14 2020-10-14 0001680367 sttk:A2020EmployeeStockPurchasePlanMember 2021-01-01 2021-01-01 0001680367 sttk:A2020EmployeeStockPurchasePlanMember 2023-01-01 2023-01-01 0001680367 sttk:A2020EmployeeStockPurchasePlanMember 2023-03-31 0001680367 sttk:A2020EmployeeStockPurchasePlanMember 2023-01-01 2023-03-31 0001680367 sttk:A2020EmployeeStockPurchasePlanMember 2022-01-01 2022-03-31 0001680367 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001680367 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001680367 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001680367 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001680367 2022-01-01 2022-12-31 0001680367 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-03-31 0001680367 us-gaap:RestrictedStockUnitsRSUMember 2022-12-31 0001680367 us-gaap:RestrictedStockUnitsRSUMember 2023-01-01 2023-03-31 0001680367 us-gaap:RestrictedStockUnitsRSUMember 2023-03-31 0001680367 us-gaap:EmployeeStockOptionMember sttk:A2020StockIncentivePlanMember sttk:BlackScholesOptionPricingModelMember 2023-01-01 2023-03-31 0001680367 us-gaap:EmployeeStockOptionMember sttk:A2020StockIncentivePlanMember sttk:BlackScholesOptionPricingModelMember 2022-01-01 2022-03-31 0001680367 us-gaap:EmployeeStockOptionMember sttk:A2020StockIncentivePlanMember sttk:MonteCarloOptionPricingModelMember 2023-01-01 2023-03-31 0001680367 us-gaap:EmployeeStockOptionMember sttk:A2020StockIncentivePlanMember sttk:MonteCarloOptionPricingModelMember 2022-01-01 2022-03-31 0001680367 us-gaap:EmployeeStockMember sttk:A2020EmployeeStockPurchasePlanMember sttk:BlackScholesOptionPricingModelMember 2023-01-01 2023-03-31 0001680367 us-gaap:EmployeeStockMember sttk:A2020EmployeeStockPurchasePlanMember sttk:BlackScholesOptionPricingModelMember 2022-01-01 2022-03-31 shares iso4217:USD iso4217:USD shares sttk:candidate pure sttk:tranch 0001680367 false 2023 Q1 --12-31 http://fasb.org/us-gaap/2022#LicenseMember http://fasb.org/us-gaap/2022#LicenseMember P4Y 10-Q true 2023-03-31 false 001-39593 Shattuck Labs, Inc. DE 81-2575858 500 W. 5th Street Suite 1200 Austin TX 78701 512 900-4690 Common Stock, par value $0.0001 per share STTK NASDAQ Yes Yes Non-accelerated Filer true true false false 42471288 66043000 47379000 69452000 113901000 22342000 23304000 157837000 184584000 16887000 17671000 2953000 3069000 177677000 205324000 5128000 7170000 10881000 17795000 16009000 24965000 4014000 4202000 20023000 29167000 0.0001 0.0001 300000000 300000000 42460258 42460258 42390586 42390586 5000 5000 397724000 396041000 -339000 -877000 -239736000 -219012000 157654000 176157000 177677000 205324000 57000 0 16667000 19187000 5051000 4979000 21718000 24166000 -21661000 -24166000 937000 -362000 -20724000 -24528000 538000 33000 -20186000 -24495000 -0.49 -0.49 -0.58 -0.58 42439204 42439204 42357625 42357625 42390586 5000 396041000 -877000 -219012000 176157000 11888 39000 39000 73937 16153 39000 39000 1683000 1683000 538000 538000 -20724000 -20724000 42460258 5000 397724000 -339000 -239736000 157654000 42338898 5000 389408000 -560000 -117067000 271786000 39616 134000 134000 1513000 1513000 33000 33000 -24528000 -24528000 42378514 5000 391055000 -527000 -141595000 248938000 -20724000 -24528000 1683000 1513000 1014000 472000 85000 65000 213000 -981000 -1462000 -3699000 -30000 -25000 -2197000 -7738000 -7356000 -601000 -188000 -165000 -57000 0 -26461000 -26277000 75000 2488000 -45200000 12894000 45125000 -15382000 39000 134000 39000 0 0 134000 18664000 -41525000 47379000 92268000 66043000 50743000 0 5447000 0 2945000 500000 0 155000 319000 Organization and Description of Business <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Shattuck Labs, Inc. (the “Company”) was incorporated in 2016 in the State of Delaware and is a clinical-stage biopharmaceutical company developing dual-sided fusion proteins, including its Agonist Redirected Checkpoint (“ARC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">®</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) and gamma delta T cell engager (“GADLEN</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.2pt;font-weight:400;line-height:120%;position:relative;top:-2.8pt;vertical-align:baseline">™</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">”) platforms, as novel classes of biologic medicines capable of multifunctional activity with potential applications in oncology and inflammatory diseases. Using its proprietary technology, the Company is building a pipeline of therapeutics, initially focused on the treatment of solid tumors and hematologic malignancies. The Company has one clinical-stage product candidate, SL-172154, and has several compounds in preclinical development. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has incurred losses and negative cash flows from operations since inception and has an accumulated deficit of $239.7 million as of March 31, 2023. The Company anticipates incurring additional losses and negative cash flows from operations until such time, if ever, that it can generate significant sales of its product candidates currently in development, and is highly dependent on its ability to find additional sources of funding in the form of licensing of its technology, collaboration agreements and/or public and private debt and equity financings. Adequate additional funding may not be available to the Company on acceptable terms, or at all. The failure to raise funds as and when needed could have a negative impact on the Company’s financial condition and ability to pursue its clinical operations, research and development and commercialization of its product candidates. Management believes that the Company’s cash and cash equivalents and investments of $135.5 million as of March 31, 2023 are sufficient to fund projected operations of the Company for at least the next twelve months. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Global Economic Considerations</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the global macroeconomic environment is uncertain, and could be negatively affected by, among other things, increased U.S. trade tariffs and trade disputes with other countries, instability in the global capital and credit markets, supply chain weaknesses, instability in the geopolitical environment, including as a result of the Russian invasion of Ukraine and other political tensions, and lingering effects of the COVID-19 pandemic. Such challenges have caused, and may continue to cause, recession fears, rising interest rates, foreign exchange volatility and inflationary pressures. At this time, we are unable to quantify the potential effects of this economic instability on our future operations.</span></div> 1 -239700000 135500000 Basis of Presentation and Summary of Significant Accounting Policies <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Financial Statements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position, its results of operations, statements of changes in stockholders’ equity and cash flows for the interim periods presented. Operating results for interim periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The interim financial statements presented herein do not contain all required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed financial statements should be read in conjunction with the annual audited financial statements and related notes in our Annual Report on Form 10-K for the year ended December 31, 2022. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management’s estimates.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one segment.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company’s financial instruments, including investments and accounts payable, approximate fair value due to the short-term nature of those instruments.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. While the Company has not experienced any losses, the recent failure of Silicon Valley Bank (“SVB”), at which the Company held cash, exposed the Company to significant credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors. The Company is in the process of transferring its cash to an alternate depository institution, the financial position of which management believes does not expose the Company to significant credit risk. Where possible, the Company will also continue to hold its excess cash in investments and money market accounts to further limit exposure. The Company does not believe that it is subject to other unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract manufacturing organizations (“CMOs”) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract research organizations (“CROs”) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. Cash and cash equivalents consisted of $0.8 million held in operating accounts and $65.2 million held in money market funds as of March 31, 2023, and $3.5 million held in operating accounts and $43.9 million held in money market funds as of December 31, 2022. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income (loss), a component of stockholders’ equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. As of March 31, 2023 and December 31, 2022, there were no impairments related to credit losses of investments. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Impairment of Long-Lived Assets</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets. There were no impairments of long-lived assets for the three months ended March 31, 2023 and 2022.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The classification of the Company’s leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company’s operating leases is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirement of Accounting Standards Codification (“ASC”) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Financial Accounting Standards Board (“FASB”) to leases with a term of 12 months or less for all classes of assets.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments and Contingencies</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 450-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the FASB to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 606”). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">identify the contract(s) with a customer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">determine the transaction price; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company’s arrangements may consist of a license of, or options to license, the Company’s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources and (ii) are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company’s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company’s collaboration revenue arrangements may include the following: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company considered the guidance in ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and will recognize the payments received from these agreements as revenue when the related costs are incurred. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A substantial portion of the Company’s ongoing research and development activities are conducted by third-party service providers, including CROs and CMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO or outside service provider, the payments will be recorded as a prepaid asset, which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company’s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company’s accruals that could materially affect the Company’s results of operations. </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Loss Per Share </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock or convertible notes, if any, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of March 31, 2023 and 2022, as they would be anti-dilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,261,439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,460,911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">652,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">313,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,914,037 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,774,301 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Comprehensive Income (Loss) </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on investments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div> <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited interim condensed financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”).</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unaudited Interim Condensed Financial Statements </span></div>In the opinion of management, the accompanying interim financial statements include all normal and recurring adjustments (which consist primarily of accruals, estimates and assumptions that impact the financial statements) considered necessary to present fairly the Company’s financial position, its results of operations, statements of changes in stockholders’ equity and cash flows for the interim periods presented. Operating results for interim periods presented are not necessarily indicative of the results that may be expected for the year ending December 31, 2023. The interim financial statements presented herein do not contain all required disclosures under GAAP for annual financial statements. The accompanying unaudited interim condensed financial statements should be read in conjunction with the annual audited financial statements and related notes in our Annual Report on Form 10-K for the year ended December 31, 2022. <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant estimates and assumptions reflected in these financial statements include, but are not limited to, revenue recognition, </span></div>the accrual of research and development expenses, and the valuation of stock-based awards. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates, if any, are recorded in the period in which they become known and actual results could differ from management’s estimates. <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company views its operations and manages its business as one segment.</span></div> <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Financial Instruments </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value is defined as the price that would be received upon the sale of an asset or paid upon the transfer of a liability in an orderly transaction between market participants at the measurement date and in the principal or most advantageous market for that asset or liability. Fair value measurements are classified and disclosed in one of the following categories: </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 1: Observable inputs such as quoted prices in active markets for identical assets the reporting entity has the ability to access as of the measurement date; </span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 2: Inputs, other than quoted prices in active markets, that are observable either directly or indirectly; and</span></div><div style="margin-top:6pt;padding-left:31.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Level 3: Unobservable inputs in which there is little or no market data, which require the reporting entity to develop its own assumptions. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value measurements are classified based on the lowest level of input that is significant to the measurement. The Company’s assessment of the significance of a particular input to the fair value measurement requires judgment, which may affect the valuation of the assets and liabilities and their placement within the fair value hierarchy levels. The determination of the fair values stated below takes into account the market for its financial assets and liabilities, the associated credit risk and other factors as required. The Company considers active markets as those in which transactions for the assets or liabilities occur with sufficient frequency and volume to provide pricing information on an ongoing basis. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management believes that the carrying amounts of the Company’s financial instruments, including investments and accounts payable, approximate fair value due to the short-term nature of those instruments.</span></div> <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentration of Risk </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to concentrations of credit risk primarily consist of cash, cash equivalents and investments. The Company maintains its cash and cash equivalents at two accredited financial institutions in amounts that exceed federally-insured limits. While the Company has not experienced any losses, the recent failure of Silicon Valley Bank (“SVB”), at which the Company held cash, exposed the Company to significant credit risk prior to the completion by the Federal Deposit Insurance Corporation of the resolution of SVB in a manner that fully protected all depositors. The Company is in the process of transferring its cash to an alternate depository institution, the financial position of which management believes does not expose the Company to significant credit risk. Where possible, the Company will also continue to hold its excess cash in investments and money market accounts to further limit exposure. The Company does not believe that it is subject to other unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company invests in only U.S. Treasury securities that management believes protects the Company from risk of default and impairment of value.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is highly dependent on a limited number of contract manufacturing organizations (“CMOs”) to supply drug products for its research and development activities of its programs, including clinical trials and non-clinical studies. These programs could be adversely affected by a significant interruption in the supply of such drug products. </span></div>The Company is highly dependent on a limited number of contract research organizations (“CROs”) and third-party service providers to manage and support its clinical trials. These programs could be adversely affected by a significant disruption in services provided by these CROs and third parties. Cash and Cash Equivalents The Company considers all demand deposits with financial institutions and all highly liquid investments with original maturities of 90 days or less at the date of purchase to be cash and cash equivalents. 800000 65200000 3500000 43900000 Investments The Company’s investments consist of highly-rated U.S. Treasury securities and have been classified as available-for-sale and are carried at estimated fair value as determined based upon quoted market prices. Management determines the appropriate classification of its investment securities at the time of purchase. The Company may hold securities with stated maturities greater than one year. All available-for-sale securities are considered available to support current operations and are classified as current assets. Credit impairments for available-for-sale securities are recorded through an allowance rather than a direct write-down of the security and are recorded through a charge to the statements of operations. Unrealized gains or losses not related to credit impairments are recorded in accumulated other comprehensive income (loss), a component of stockholders’ equity, until realized. The Company reviews available-for-sale debt securities for impairments related to credit losses and other factors each quarter. Impairment of Long-Lived AssetsLong-lived assets are reviewed for indications of possible impairment whenever events or changes in circumstance indicate that the carrying amount of an asset may not be recoverable. Recoverability is measured by comparison of the carrying amounts to the future undiscounted cash flows attributable to these assets. An impairment loss is recognized to the extent an asset group is not recoverable and the carrying amount exceeds the projected discounted future cash flows arising from these assets. 0 0 <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Leases</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if an arrangement is a lease at inception. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent the Company’s obligation to make lease payments arising from the lease. The classification of the Company’s leases as operating or finance leases, along with the initial measurement and recognition of the associated ROU assets and lease liabilities, are performed at the lease commencement date. The measurement of lease liabilities is based on the present value of future lease payments over the lease term. As the Company’s leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of future lease payments. The ROU asset is based on the measurement of the lease liability and also includes any lease payments made prior to or on lease commencement and excludes lease incentives and initial direct costs incurred, as applicable. The lease terms may include options to extend or terminate the lease when it is reasonably certain the Company will exercise any such options. Rent expense for the Company’s operating leases is recognized on a straight-line basis over the lease term. The Company has elected to not apply the recognition requirement of Accounting Standards Codification (“ASC”) 842, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the Financial Accounting Standards Board (“FASB”) to leases with a term of 12 months or less for all classes of assets.</span></div> <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Commitments and Contingencies</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows ASC 450-20, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contingencies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the FASB to report accounting for contingencies. Certain conditions may exist as of the date the condensed financial statements are issued, which may result in a loss to the Company but which will only be resolved when one or more future events occur or fail to occur. The Company assesses such contingent liabilities, and such assessment inherently involves an exercise of judgment. In assessing loss contingencies related to legal proceedings that are pending against the Company or unasserted claims </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that may result in such proceedings, the Company evaluates the perceived merits of any legal proceedings or unasserted claims as well as the perceived merits of the amount of relief sought or expected to be sought therein.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the assessment of a contingency indicates that it is probable that a material loss has been incurred and the amount of the liability can be estimated, then the estimated liability would be accrued in the Company’s condensed financial statements. If the assessment indicates that a potential material loss contingency is not probable but is reasonably possible, or is probable but cannot be estimated, then the nature of the contingent liability, and an estimate of the range of possible losses, if determinable and material, would be disclosed.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Loss contingencies considered remote are generally not disclosed unless they involve guarantees, in which case the guarantees would be disclosed.</span></div> <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration revenue is recognized in accordance with ASC 606, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (“ASC 606”). Arrangements with collaborators may include licenses to intellectual property, research and development services, manufacturing services for clinical and commercial supply and participation on joint steering committees. The Company evaluates the promised goods or services in the contract to determine which promises, or group of promises, represent performance obligations. In contemplation of whether a promised good or service meets the criteria required of a performance obligation, the Company considers the stage of development of the underlying intellectual property, the capabilities and expertise of the customer relative to the underlying intellectual property and whether the promised goods or services are integral to or dependent on other promises in the contract. When accounting for an arrangement that contains multiple performance obligations, the Company must develop judgmental assumptions, which may include market conditions, reimbursement rates for personnel costs, development timelines and probabilities of regulatory success to determine the stand-alone selling price for each performance obligation identified in the contract. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon the amendment of an existing agreement, the Company evaluates whether the amendment represents a modification to an existing contract that would be recorded through a cumulative catch-up to revenue, or a separate contract. If it is determined that it is a separate contract, the Company will evaluate the necessary revenue recognition through the five-step process described below. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When the Company concludes that a contract should be accounted for as a combined performance obligation and recognized over time, the Company must then determine the period over which revenue should be recognized and the method by which to measure revenue. The Company generally recognizes revenue using a cost-based input method. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes collaboration revenue in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services when its customer or collaborator obtains control of promised goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the following five steps are performed: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">i.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:12.73pt">identify the contract(s) with a customer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:9.96pt">identify the performance obligations in the contract; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iii.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.19pt">determine the transaction price; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">iv.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:7.73pt">allocate the transaction price to the performance obligations within the contract; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">v.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">recognize revenue when (or as) the entity satisfies a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company only applies the five-step model to contracts when it determines that it is probable it will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within the contract to determine whether each promised good or service is a performance obligation. The promised goods or services in the Company’s arrangements may consist of a license of, or options to license, the Company’s intellectual property and research, development and manufacturing services. The Company may provide options to additional items in such arrangements, which are accounted for as separate contracts when the customer elects to exercise such options, unless the option provides a material right to the </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">customer. Performance obligations are promises in a contract to transfer a distinct good or service to the customer that (i) the customer can benefit from on its own or together with other readily available resources and (ii) are separately identifiable from other promises in the contract. Goods or services that are not individually distinct performance obligations are combined with other promised goods or services until such combined group of promises meet the requirements of a performance obligation. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines transaction price based on the amount of consideration the Company expects to receive for transferring the promised goods or services in the contract. Consideration may be fixed, variable or a combination of both. At contract inception for arrangements that include variable consideration, the Company estimates the probability and extent of consideration it expects to receive under the contract utilizing either the most-likely amount method or expected amount method, whichever best estimates the amount expected to be received. The Company then considers any constraints on the variable consideration and includes variable consideration in the transaction price to the extent it is deemed probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company then allocates the transaction price to each performance obligation based on the relative standalone selling price and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied. For performance obligations that consist of licenses and other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records amounts as accounts receivable when the right to consideration is deemed unconditional. When consideration is received, or such consideration is unconditionally due, from a customer prior to transferring goods or services to the customer under the terms of a contract, a contract liability is recorded as deferred revenue. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the revenue recognition criteria are recognized as deferred revenue in the Company’s accompanying balance sheet. Deferred revenues expected to be recognized as revenue within the 12 months following the balance sheet date are classified as a current liability. Deferred revenues not expected to be recognized as revenue within the 12 months following the balance sheet date are classified as non-current liabilities. </span></div><div style="margin-top:6pt;padding-left:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Company’s collaboration revenue arrangements may include the following: </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Up-front License Fees: If a license is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenues from nonrefundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgment to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. The Company evaluates the measure of progress each reporting period and, if necessary, adjusts the measure of performance and related revenue recognition. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone Payments: At the inception of an agreement that includes research and development milestone payments, the Company evaluates each milestone to determine when and how much of the milestone to include in the transaction price. The Company first estimates the amount of the milestone payment that the Company could receive using either the expected value or the most-likely amount approach. The Company primarily uses the most-likely amount approach as that approach is generally most predictive for milestone payments with a binary outcome. The Company then considers whether any portion of that estimated amount is subject to the variable consideration constraint (that is, whether it is probable that a significant reversal of cumulative revenue would not occur upon resolution of the uncertainty). The Company updates the estimate of variable consideration included in the transaction price at each reporting date which includes updating the assessment of the likely amount of consideration and the application of the constraint to reflect current facts and circumstances. </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties: For arrangements that include sales-based royalties, including milestone payments based on a level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company will </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">recognize revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not granted a development and commercialization license nor recognized any revenue related to sales-based royalties or milestone payments based on the level of sales. </span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and Development Services: The Company will record costs associated with development and process optimization activities as research and development expenses in the statements of operations and comprehensive loss consistent with ASC 730, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research and Development.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company considered the guidance in ASC 808, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span> and will recognize the payments received from these agreements as revenue when the related costs are incurred. <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Costs </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development costs are expensed as incurred, and include salaries, stock-based compensation and other personnel-related costs, equipment and supplies, depreciation, nonclinical studies, clinical trials and manufacturing development activities. </span></div>A substantial portion of the Company’s ongoing research and development activities are conducted by third-party service providers, including CROs and CMOs. The Company accrues for expenses resulting from obligations under agreements with CROs, CMOs and other outside service providers for which payment flows do not match the periods over which materials or services are provided to the Company. Accruals are recorded based on estimates of services received and efforts expended pursuant to agreements established with CROs, CMOs and other outside service providers. These estimates are typically based on contracted amounts applied to the proportion of work performed and determined through an evaluation of the progress or stage of completion of the services. In the event advance payments are made to a CRO, CMO or outside service provider, the payments will be recorded as a prepaid asset, which will be amortized as the contracted services are performed. As actual costs become known, the Company adjusts its accruals and prepaid assets accordingly. Inputs, such as the services performed, the number of patients enrolled or the study duration, may vary from the Company’s estimates, resulting in adjustments to research and development expense in future periods. The Company makes significant judgments and estimates in determining the accrual and/or prepaid balance in each reporting period and changes in these estimates may result in material changes to the Company’s accruals that could materially affect the Company’s results of operations. Net Loss Per Share Basic loss per share of common stock is computed by dividing net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during each period. Diluted loss per share of common stock includes the effect, if any, from the potential exercise or conversion of securities, such as redeemable convertible preferred stock or convertible notes, if any, stock options and unvested shares of restricted stock, which would result in the issuance of incremental shares of common stock. For diluted net loss per share, the weighted-average number of shares of common stock is the same for basic net loss per share due to the fact that when a net loss exists, dilutive securities are not included in the calculation as the impact is anti-dilutive. <span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following potentially dilutive securities have been excluded from the computation of diluted weighted-average shares of common stock outstanding as of March 31, 2023 and 2022, as they would be anti-dilutive:</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.092%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.483%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.484%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,261,439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,460,911 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested restricted stock</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">652,598 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">313,390 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,914,037 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,774,301 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table> 5261439 3460911 652598 313390 5914037 3774301 Other Comprehensive Income (Loss) Other comprehensive income (loss) is defined as the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Other comprehensive income (loss) is comprised of the net loss and unrealized gains and losses on investments. <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div> Investments <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company’s available for sale investments by major security type (amounts in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.215%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,791 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(339)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,452 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.215%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,778 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113,901 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,778 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(877)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113,901 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s investment instruments and cash and cash equivalents are classified using Level 1 inputs within the fair value hierarchy and are valued using quoted market prices, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency. Debt securities have a weighted-average maturity of 0.24 years as of March 31, 2023.</span></div> <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table represents the Company’s available for sale investments by major security type (amounts in thousands): </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.215%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31, 2023</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized <br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,791 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(339)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,452 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,791 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(339)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69,452 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:1pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.675%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.214%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.215%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31, 2022</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Amortized<br/>Cost</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Gross Unrealized Loss</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Total Fair Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investments:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 5.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. Treasury securities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,778 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(877)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113,901 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total investments</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114,778 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(877)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113,901 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 69791000 -339000 69452000 69791000 -339000 69452000 114778000 -877000 113901000 114778000 -877000 113901000 P0Y2M26D Accrued Expenses and Other Current Liabilities<div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (amounts in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development contract costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,881 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,795 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accrued expenses and other current liabilities consisted of the following (amounts in thousands):</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:73.258%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.400%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.401%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">March 31,<br/>2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">December 31,<br/>2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development contract costs</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6,650 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11,256 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Litigation settlement</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,400 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation and related benefits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,203 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3,967 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,628 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,172 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total accrued expenses and other current liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,881 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17,795 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 6650000 11256000 1400000 1400000 1203000 3967000 1628000 1172000 10881000 17795000 Commitments and Contingencies <div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Leases </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases certain office space, laboratory facilities, and equipment. These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain of these leases also include renewal options at the election of the Company to renew or extend the lease. These optional periods have not been considered in the determination of the ROU assets or lease liabilities associated with these leases as the Company did not consider it reasonably certain it would exercise the options. The Company performed evaluations of its contracts and determined it has operating leases. There have been no material changes in our operating leases as compared to operating leases disclosed in our Annual Report on Form 10-K for the year ended December 31, 2022.</span></div><div style="margin-top:12pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nighthawk Biosciences, Inc. License Agreement </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a license agreement with Nighthawk Biosciences, Inc. (“Nighthawk”), the Company is required to make payments of up to $20.6 million in aggregate for the achievement of specified development, regulatory and commercial sales milestones for certain licensed products. The Company paid $0.1 million to Nighthawk in the three months ended March 31, 2023 as a milestone payment for the Company’s completion of a Phase 1 clinical trial for SL-172154. The Company is required to pay Nighthawk a percentage of upfront fees or other non-royalty payments not tied to milestone events that it receives in connection with certain sublicenses of the licensed patents. The Company is also required to pay Nighthawk a royalty on all of its worldwide net sales, those of its affiliates, and sublicenses of certain licensed patents in the low single digits. The Company has not recorded a liability for the aforementioned payments given the achievement of specified development, regulatory and commercial sales milestones for certain licensed products is not probable as of the balance sheet date.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may become involved in various legal actions arising in the ordinary course of business. On January 31, 2022 and February 11, 2022, putative class action lawsuits were filed in the U.S. District Court for the Eastern District of New York against us and certain of the Company’s officers and directors. The cases were consolidated on June 2, 2022, and the plaintiffs filed an amended complaint on July 1, 2022. The amended complaint cites the volatility in the Company’s common stock and alleges that the defendants made or are responsible for misleading omissions regarding the Company’s clinical trial results and the collaboration agreement with Millennium Pharmaceuticals, Inc., a wholly-owned subsidiary of Takeda Pharmaceutical Company, Ltd. The parties reached a settlement in principle of the plaintiffs’ claims in the amount of $1.4 million on November 2, 2022. The settlement is subject to a definitive settlement agreement, notice to stockholders and court approval. The parties filed their motion for preliminary approval of the settlement agreement with the court on December 14, 2022, and, as of May 8, 2023, that motion is pending. The Company has accrued the settlement amount in accrued expenses and other current liabilities as of March 31, 2023.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contractual Obligations </span></div>Contractual obligations represent future cash commitments and liabilities under agreements with third parties, and exclude contingent liabilities for which the Company cannot reasonably predict future payment. The Company’s contractual obligations result primarily from obligations for various CMOs and CROs, which include potential payments that may be required under its agreements. The contracts also contain variable costs and milestones that are hard to predict, as they are based on such things as patients enrolled and clinical trial sites. The timing of payments and actual amounts paid under CMO and CRO agreements may be different depending on the timing of receipt of goods or services or changes to agreed-upon terms or amounts for some obligations. Such agreements are cancellable upon written notice by the Company and, therefore, are not long-term liabilities. 20600000 100000 0 1400000 EquityThe Company is authorized to issue up to 300,000,000 shares of common stock and 10,000,000 shares of preferred stock, all with a par value of $0.0001 per share. The holders of the Company’s common stock are entitled to one vote per share on all matters submitted to a vote of stockholders. The Company’s common stock is not entitled to preemptive rights, and is not subject to conversion, redemption or sinking fund provisions. Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of the Company’s common stock will receive ratably any dividends declared by the Company’s board of directors (“Board”) out of funds legally available. In the event of the Company’s liquidation, dissolution or winding-up, the holders of the Company’s common stock will be entitled to share ratably in all assets remaining after payment of or provision for any liabilities. As of the periods presented, no common stock dividends had been declared by the Board. At March 31, 2023, none of the 10,000,000 shares of preferred stock were outstanding, and the Company has no present plans to issue any shares of preferred stock. 300000000 10000000 0.0001 0.0001 0 10000000 Stock-Based Compensation<div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Equity Incentive Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2020, the Company adopted the 2020 Stock Incentive Plan (the “2020 Plan”) which, as of the adoption date, replaced the 2016 Stock Incentive Plan. Under the 2020 Plan, the share reserve automatically </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increases on January 1st of each year beginning in 2021 and ending with a final increase on January 1, 2030 in an amount equal to 4% of the Company’s outstanding common shares on December 31st of the preceding calendar year. The Board may provide that there will be no increase in the share reserve for any such year or that the increase in the share reserve may be smaller than would otherwise occur. On January 1, 2023, the share reserve automatically increased by 1,695,623 shares. As of March 31, 2023, there were 3,739,124 shares available for future grants. The 2020 Plan permits the granting of options, stock appreciation rights, restricted stock units (“RSUs”), performance stock and performance cash awards. The terms of the agreements under the 2020 Plan are determined by the Board. The Company’s awards generally vest over four years and have a term of 10 years. In 2023, the Company granted 165,050 awards that vest in three equal tranches based on the Company achieving a certain closing share price for each tranche for 30 consecutive trading days on or before the <span style="-sec-ix-hidden:id3VybDovL2RvY3MudjEvZG9jOmFiNzVkNzNhZDhlNTRkZjM4M2U1NDgwZmRkZDZkY2I1L3NlYzphYjc1ZDczYWQ4ZTU0ZGYzODNlNTQ4MGZkZGQ2ZGNiNV8zNjUvZnJhZzpiMDJlN2NmMWZkZDM0Zjk2ODNmMDUzMzI5MDNiZTFmNS90ZXh0cmVnaW9uOmIwMmU3Y2YxZmRkMzRmOTY4M2YwNTMzMjkwM2JlMWY1XzI3NDg3NzkwOTE4MDA_cc775207-fe02-4c9b-8e4e-2107d58e985d">four</span>th anniversary of the grant date.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2020 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The 2020 Employee Stock Purchase Plan (“2020 ESPP”) became effective in October 2020. A total of 395,795 shares of common stock were reserved for issuance under the 2020 ESPP. Eligible employees may purchase shares of common stock under the 2020 ESPP at 85% of the lower of the fair market value of the Company’s common stock as of the first or the last day of each offering period. Employees are limited to contributing 15% of the employee’s eligible compensation and may not purchase more than $25,000 of stock during any calendar year or more than 600 shares during any one purchase period. The 2020 ESPP share reserve automatically increases on January 1st of each calendar year, for ten years, commencing on January 1, 2021, in an amount equal to 1% of the total number of shares of common stock outstanding on December 31st of the preceding calendar year. The Board may act prior to January 1st of a given year to provide that there will be no January 1st increase of the share reserve for such year or that the increase in the share reserve for such year will be a smaller number of shares of common stock than would otherwise occur pursuant to the preceding sentence. On January 1, 2023, the share reserve increased by 423,905 shares. As of March 31, 2023, there were 1,216,723 shares available for future grants. During the three months ended March 31, 2023 and 2022, the Company issued 11,171 and 5,227 shares of common stock for aggregate cash proceeds of $0.1 million and $0.1 million, respectively.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim condensed statements of operations and comprehensive loss (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"><tr><td style="width:1.0%"/><td style="width:70.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.648%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">814 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">827 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,683 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,513 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2020 Plan:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:48.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,209,255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,181,087 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(717)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(128,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,261,439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,174,691 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.27 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.05</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at the end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,122,655 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.28 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.55</span></td></tr></table></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options granted during the three months ended March 31, 2023 and 2022 had weighted-average grant-date fair values of $2.46 and $5.13 per share, respectively. As of March 31, 2023, the unrecognized compensation cost for options issued was $14.1 million and will be recognized over an estimated weighted-average amortization period of 2.49 years. The total intrinsic value of options exercised during the three months ended March 31, 2023 and 2022 </span></div><div style="margin-top:7pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was $0.1 million and $0.1 million, respectively. The aggregate intrinsic value of options outstanding and exercisable as of March 31, 2023 was $0.2 million.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes employee RSU activity for the three months ended March 31, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.455%"><tr><td style="width:1.0%"/><td style="width:67.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested RSUs as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">309,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">445,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(73,937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27,967)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">652,598 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.81 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized $0.2 million of stock-based compensation related to RSUs as of March 31, 2023. As of March 31, 2023, the unrecognized compensation cost for RSUs issued was $3.1 million and will be recognized over an estimated weighted-average amortization period of 3.47 years. The fair values of RSUs are based on the fair value of the Company’s common stock on the date of the grant.</span></div><div style="margin-top:6pt;padding-left:18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Fair Value of Stock Options and Shares Issued</span></div><div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for stock-based compensation by measuring and recognizing as compensation expense the fair value of all share-based payment awards made to employees, including employee stock options and restricted stock awards. The Company uses the Black-Scholes option pricing model to estimate the fair value of employee stock options that only have service or performance conditions. The Company uses the Monte Carlo pricing model to estimate the fair value of options that have market-based conditions. The inputs to both pricing models require a number of management estimates such as the expected term, volatility, risk-free interest rate and dividend yield. The fair value of stock options was determined using the methods and assumptions discussed below.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected term of employee stock options with service-based vesting is determined using the “simplified” method, whereby the expected life equals the arithmetic average of the vesting term and the original contractual term of the option due to the Company’s lack of sufficient historical data.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected stock price volatility assumption is based on the historical volatilities of the common stock of a peer group of publicly traded companies as well as the historical volatility of the Company’s common stock since the Company began trading subsequent to the Company’s initial public offering (“IPO”) in October 2020 over the period corresponding to the expected life as of the grant date. The historical volatility data was computed using the daily closing prices during the equivalent period of the calculated expected term of the stock-based awards. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of the Company’s stock price becomes available, or until circumstances change, such that the identified entities are no longer comparable companies. In the latter case, other suitable, similar entities whose share prices are publicly available would be utilized in the calculation.</span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the expected term. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">The expected dividend yield is 0% because the Company has not historically paid, and does not expect, for the foreseeable future, to pay dividends on its common stock. </span></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">•</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:5.5pt">Prior to the Company’s IPO, the Board periodically estimated the fair value of the Company’s common stock considering, among other things, contemporaneous valuations of its common stock prepared by an unrelated third-party valuation firm. Subsequent to the Company’s IPO, options are issued with a strike price no less than the market price on date of grant.</span></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company’s 2020 Plan were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"/><td style="width:68.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Monte Carlo option pricing model granted under the Company’s 2020 Plan were estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"/><td style="width:68.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company’s 2020 ESPP were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"/><td style="width:68.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 ESPP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.49</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td></tr></table></div> 0.04 1695623 3739124 P4Y P10Y 165050 3 P30D 395795 0.85 0.15 25000 600 P10Y 0.01 423905 1216723 11171 5227 100000 100000 <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded stock-based compensation expense in the following expense categories of its accompanying unaudited interim condensed statements of operations and comprehensive loss (in thousands):</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:93.269%"><tr><td style="width:1.0%"/><td style="width:70.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.645%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.002%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.648%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">814 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">827 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">869 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">686 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total stock-based compensation</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,683 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,513 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 814000 827000 869000 686000 1683000 1513000 <div style="margin-top:4pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes option activity under the 2020 Plan:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:48.375%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.886%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.983%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.023%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Remaining Life</span></div><div style="margin-bottom:2pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Years)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4,209,255 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.29 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,181,087 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercised</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(717)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.95 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(128,186)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March 31, 2023</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,261,439 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.25 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.07</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vested and expected to vest</span></td><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,174,691 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.27 </span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.05</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exercisable at the end of the period</span></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2,122,655 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.28 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.55</span></td></tr></table></div> 4209255 8.29 P8Y25D 1181087 3.57 717 2.95 128186 7.57 5261439 7.25 P8Y25D 5174691 7.27 P8Y18D 2122655 8.28 P6Y6M18D 2.46 5.13 14100000 P2Y5M26D 100000 100000 200000 200000 <div style="margin-top:7pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes employee RSU activity for the three months ended March 31, 2023:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:84.455%"><tr><td style="width:1.0%"/><td style="width:67.780%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.080%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.559%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.081%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Weighted</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Grant Date Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unvested RSUs as of December 31, 2022</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">309,477 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.22 </span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Granted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">445,025 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.57 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Released</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(73,937)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7.43 </span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Forfeited</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(27,967)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.89 </span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March 31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">652,598 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.81 </span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div> 309477 7.22 445025 3.57 73937 7.43 27967 4.89 652598 4.81 200000 3100000 P3Y5M19D 0 <div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Black-Scholes option pricing model granted under the Company’s 2020 Plan were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"/><td style="width:68.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.08</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6.08</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.9%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.6%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of options calculated using the Monte Carlo option pricing model granted under the Company’s 2020 Plan were estimated using the following assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"/><td style="width:68.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 Plan</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.00</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.00</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.0%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80.0%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.6%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.4%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td></tr></table></div><div style="margin-top:6pt;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The grant-date fair value of shares issued calculated using the Black-Scholes option pricing model under the Company’s 2020 ESPP were estimated using the following weighted-average assumptions:</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:86.057%"><tr><td style="width:1.0%"/><td style="width:68.359%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.797%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.800%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="9" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Three Months Ended March 31,</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2023</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2022</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2020 ESPP</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected term - years</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.49</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">0.49</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84.8%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81.8%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.5%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.0%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expected dividends</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">—</span></td></tr></table></div> P6Y29D P6Y29D 0.848 0.819 0.035 0.016 0 0 P4Y P4Y 0.800 0.800 0.036 0.014 0 0 P0Y5M26D P0Y5M26D 0.848 0.818 0.035 0.020 0 0 EXCEL 42 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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how.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 44 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 45 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 68 195 1 false 18 0 false 6 false false R1.htm 0000001 - Document - COVER Sheet http://www.shattucklabs.com/role/COVER COVER Cover 1 false false R2.htm 0000002 - Statement - CONDENSED BALANCE SHEETS Sheet http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS CONDENSED BALANCE SHEETS Statements 2 false false R3.htm 0000003 - Statement - CONDENSED BALANCE SHEETS - Parenthetical Sheet http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical CONDENSED BALANCE SHEETS - Parenthetical Statements 3 false false R4.htm 0000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Sheet http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS Statements 4 false false R5.htm 0000005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY Sheet http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS??? EQUITY Statements 5 false false R6.htm 0000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS Sheet http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS CONDENSED STATEMENTS OF CASH FLOWS Statements 6 false false R7.htm 0000007 - Disclosure - Organization and Description of Business Sheet http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness Organization and Description of Business Notes 7 false false R8.htm 0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies Sheet http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies Basis of Presentation and Summary of Significant Accounting Policies Notes 8 false false R9.htm 0000009 - Disclosure - Investments Sheet http://www.shattucklabs.com/role/Investments Investments Notes 9 false false R10.htm 0000010 - Disclosure - Accrued Expenses and Other Current Liabilities Sheet http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities Accrued Expenses and Other Current Liabilities Notes 10 false false R11.htm 0000011 - Disclosure - Commitments and Contingencies Sheet http://www.shattucklabs.com/role/CommitmentsandContingencies Commitments and Contingencies Notes 11 false false R12.htm 0000012 - Disclosure - Equity Sheet http://www.shattucklabs.com/role/Equity Equity Notes 12 false false R13.htm 0000013 - Disclosure - Stock-Based Compensation Sheet http://www.shattucklabs.com/role/StockBasedCompensation Stock-Based Compensation Notes 13 false false R14.htm 0000014 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies) Sheet http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies Basis of Presentation and Summary of Significant Accounting Policies (Policies) Policies http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 14 false false R15.htm 0000015 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables) Sheet http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables Basis of Presentation and Summary of Significant Accounting Policies (Tables) Tables http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies 15 false false R16.htm 0000016 - Disclosure - Investments (Tables) Sheet http://www.shattucklabs.com/role/InvestmentsTables Investments (Tables) Tables http://www.shattucklabs.com/role/Investments 16 false false R17.htm 0000017 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables) Sheet http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables Accrued Expenses and Other Current Liabilities (Tables) Tables http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities 17 false false R18.htm 0000018 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.shattucklabs.com/role/StockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.shattucklabs.com/role/StockBasedCompensation 18 false false R19.htm 0000019 - Disclosure - Organization and Description of Business (Details) Sheet http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails Organization and Description of Business (Details) Details http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness 19 false false R20.htm 0000020 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) Sheet http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details) Details http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables 20 false false R21.htm 0000021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details) Sheet http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details) Details 21 false false R22.htm 0000022 - Disclosure - Investments - Schedule of available for sale investments (Details) Sheet http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails Investments - Schedule of available for sale investments (Details) Details 22 false false R23.htm 0000023 - Disclosure - Investments - Narrative (Details) Sheet http://www.shattucklabs.com/role/InvestmentsNarrativeDetails Investments - Narrative (Details) Details 23 false false R24.htm 0000024 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of accrued expenses and other current liabilities (Details) Sheet http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails Accrued Expenses and Other Current Liabilities - Schedule of accrued expenses and other current liabilities (Details) Details 24 false false R25.htm 0000025 - Disclosure - Commitments and Contingencies - Narrative (Details) Sheet http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails Commitments and Contingencies - Narrative (Details) Details 25 false false R26.htm 0000026 - Disclosure - Equity (Details) Sheet http://www.shattucklabs.com/role/EquityDetails Equity (Details) Details http://www.shattucklabs.com/role/Equity 26 false false R27.htm 0000027 - Disclosure - Stock-Based Compensation - Narrative (Details) Sheet http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails Stock-Based Compensation - Narrative (Details) Details 27 false false R28.htm 0000028 - Disclosure - Stock-Based Compensation - Schedule of stock-based compensation expense (Details) Sheet http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails Stock-Based Compensation - Schedule of stock-based compensation expense (Details) Details 28 false false R29.htm 0000029 - Disclosure - Stock-Based Compensation - Schedule of option activity (Details) Sheet http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails Stock-Based Compensation - Schedule of option activity (Details) Details 29 false false R30.htm 0000030 - Disclosure - Stock-Based Compensation - Schedule of restricted stock activity (Details) Sheet http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails Stock-Based Compensation - Schedule of restricted stock activity (Details) Details 30 false false R31.htm 0000031 - Disclosure - Stock-Based Compensation - Schedule of valuation assumptions (Details) Sheet http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails Stock-Based Compensation - Schedule of valuation assumptions (Details) Details 31 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 - sttk-20230331.htm 4 sttk-20230331.htm sttk-20230331.xsd sttk-20230331_cal.xml sttk-20230331_def.xml sttk-20230331_lab.xml sttk-20230331_pre.xml sub-certxsection302xceoxq1.htm sub-certxsection302xcfoxq1.htm sub-certxsection906ofthesa.htm http://fasb.org/us-gaap/2022 http://xbrl.sec.gov/dei/2022 true true JSON 48 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "sttk-20230331.htm": { "axisCustom": 0, "axisStandard": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 312, "http://xbrl.sec.gov/dei/2022": 31 }, "contextCount": 68, "dts": { "calculationLink": { "local": [ "sttk-20230331_cal.xml" ] }, "definitionLink": { "local": [ "sttk-20230331_def.xml" ] }, "inline": { "local": [ "sttk-20230331.htm" ] }, "labelLink": { "local": [ "sttk-20230331_lab.xml" ] }, "presentationLink": { "local": [ "sttk-20230331_pre.xml" ] }, "schema": { "local": [ "sttk-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 268, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 3, "http://xbrl.sec.gov/dei/2022": 5, "total": 8 }, "keyCustom": 15, "keyStandard": 180, "memberCustom": 5, "memberStandard": 12, "nsprefix": "sttk", "nsuri": "http://www.shattucklabs.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - COVER", "menuCat": "Cover", "order": "1", "role": "http://www.shattucklabs.com/role/COVER", "shortName": "COVER", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000010 - Disclosure - Accrued Expenses and Other Current Liabilities", "menuCat": "Notes", "order": "10", "role": "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities", "shortName": "Accrued Expenses and Other Current Liabilities", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000011 - Disclosure - Commitments and Contingencies", "menuCat": "Notes", "order": "11", "role": "http://www.shattucklabs.com/role/CommitmentsandContingencies", "shortName": "Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000012 - Disclosure - Equity", "menuCat": "Notes", "order": "12", "role": "http://www.shattucklabs.com/role/Equity", "shortName": "Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000013 - Disclosure - Stock-Based Compensation", "menuCat": "Notes", "order": "13", "role": "http://www.shattucklabs.com/role/StockBasedCompensation", "shortName": "Stock-Based Compensation", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000014 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "14", "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000015 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "menuCat": "Tables", "order": "15", "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "div", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000016 - Disclosure - Investments (Tables)", "menuCat": "Tables", "order": "16", "role": "http://www.shattucklabs.com/role/InvestmentsTables", "shortName": "Investments (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000017 - Disclosure - Accrued Expenses and Other Current Liabilities (Tables)", "menuCat": "Tables", "order": "17", "role": "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables", "shortName": "Accrued Expenses and Other Current Liabilities (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000018 - Disclosure - Stock-Based Compensation (Tables)", "menuCat": "Tables", "order": "18", "role": "http://www.shattucklabs.com/role/StockBasedCompensationTables", "shortName": "Stock-Based Compensation (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "sttk:NumberOfClinicalStageProductCandidates", "reportCount": 1, "unique": true, "unitRef": "candidate", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000019 - Disclosure - Organization and Description of Business (Details)", "menuCat": "Details", "order": "19", "role": "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails", "shortName": "Organization and Description of Business (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "sttk:NumberOfClinicalStageProductCandidates", "reportCount": 1, "unique": true, "unitRef": "candidate", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000002 - Statement - CONDENSED BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS", "shortName": "CONDENSED BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000020 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)", "menuCat": "Details", "order": "20", "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": "-5", "lang": "en-US", "name": "us-gaap:TangibleAssetImpairmentCharges", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000021 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)", "menuCat": "Details", "order": "21", "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies - Schedule of anti-dilutive securities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "div", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": "0", "first": true, "lang": "en-US", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000022 - Disclosure - Investments - Schedule of available for sale investments (Details)", "menuCat": "Details", "order": "22", "role": "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails", "shortName": "Investments - Schedule of available for sale investments (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000023 - Disclosure - Investments - Narrative (Details)", "menuCat": "Details", "order": "23", "role": "http://www.shattucklabs.com/role/InvestmentsNarrativeDetails", "shortName": "Investments - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DebtSecuritiesAvailableForSaleTerm", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "sttk:AccruedResearchAndContractCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000024 - Disclosure - Accrued Expenses and Other Current Liabilities - Schedule of accrued expenses and other current liabilities (Details)", "menuCat": "Details", "order": "24", "role": "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails", "shortName": "Accrued Expenses and Other Current Liabilities - Schedule of accrued expenses and other current liabilities (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "sttk:AccruedResearchAndContractCostsCurrent", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "sttk:LicenseAgreementRoyaltyPaymentsMaximum", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000025 - Disclosure - Commitments and Contingencies - Narrative (Details)", "menuCat": "Details", "order": "25", "role": "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails", "shortName": "Commitments and Contingencies - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": "-5", "first": true, "lang": "en-US", "name": "sttk:LicenseAgreementRoyaltyPaymentsMaximum", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "us-gaap:CommonStockSharesAuthorized", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockSharesAuthorized", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000026 - Disclosure - Equity (Details)", "menuCat": "Details", "order": "26", "role": "http://www.shattucklabs.com/role/EquityDetails", "shortName": "Equity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "ix:continuation", "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:PreferredStockSharesAuthorized", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000027 - Disclosure - Stock-Based Compensation - Narrative (Details)", "menuCat": "Details", "order": "27", "role": "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails", "shortName": "Stock-Based Compensation - Narrative (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": "2", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "reportCount": 1, "unique": true, "unitRef": "usdPerShare", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000028 - Disclosure - Stock-Based Compensation - Schedule of stock-based compensation expense (Details)", "menuCat": "Details", "order": "28", "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails", "shortName": "Stock-Based Compensation - Schedule of stock-based compensation expense (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i553413b499654651890bbd3c2a30bad5_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i5bf96c6dc4c34a0eb07a3c1f2cf1a979_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "reportCount": 1, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000029 - Disclosure - Stock-Based Compensation - Schedule of option activity (Details)", "menuCat": "Details", "order": "29", "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails", "shortName": "Stock-Based Compensation - Schedule of option activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unitRef": "usdPerShare", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000003 - Statement - CONDENSED BALANCE SHEETS - Parenthetical", "menuCat": "Statements", "order": "3", "role": "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical", "shortName": "CONDENSED BALANCE SHEETS - Parenthetical", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "us-gaap:CommonStockSharesOutstanding", "span", "div", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i54a9b5c3ecd3444eb11bc87522cd5887_I20230331", "decimals": "INF", "lang": "en-US", "name": "us-gaap:CommonStockSharesIssued", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R30": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "iaf0a0042588b4fd2ac8a83479b491708_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000030 - Disclosure - Stock-Based Compensation - Schedule of restricted stock activity (Details)", "menuCat": "Details", "order": "30", "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails", "shortName": "Stock-Based Compensation - Schedule of restricted stock activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "iaf0a0042588b4fd2ac8a83479b491708_I20221231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R31": { "firstAnchor": { "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i428ae4dc142344e4867b47e344b894fe_D20230101-20230331", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "reportCount": 1, "unitRef": "number", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000031 - Disclosure - Stock-Based Compensation - Schedule of valuation assumptions (Details)", "menuCat": "Details", "order": "31", "role": "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails", "shortName": "Stock-Based Compensation - Schedule of valuation assumptions (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "ix:continuation", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "ia3286ad000a74fb2b534f75b6f23f669_D20230101-20230331", "decimals": null, "lang": "en-US", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000004 - Statement - CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "menuCat": "Statements", "order": "4", "role": "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS", "shortName": "CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "ibf15edfb0127444c8297ddfefadc5003_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000005 - Statement - CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY", "menuCat": "Statements", "order": "5", "role": "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "shortName": "CONDENSED STATEMENTS OF CHANGES IN STOCKHOLDERS\u2019 EQUITY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "ibf15edfb0127444c8297ddfefadc5003_I20211231", "decimals": "INF", "first": true, "lang": "en-US", "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "shares", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": "-3", "first": true, "lang": "en-US", "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "usd", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "0000006 - Statement - CONDENSED STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS", "shortName": "CONDENSED STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": "-3", "lang": "en-US", "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "usd", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000007 - Disclosure - Organization and Description of Business", "menuCat": "Notes", "order": "7", "role": "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness", "shortName": "Organization and Description of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000008 - Disclosure - Basis of Presentation and Summary of Significant Accounting Policies", "menuCat": "Notes", "order": "8", "role": "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies", "shortName": "Basis of Presentation and Summary of Significant Accounting Policies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "0000009 - Disclosure - Investments", "menuCat": "Notes", "order": "9", "role": "http://www.shattucklabs.com/role/Investments", "shortName": "Investments", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "sttk-20230331.htm", "contextRef": "i281f9c1ade6d4fa2a31f9fc6afa6b84e_D20230101-20230331", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 18, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus", "terseLabel": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus", "terseLabel": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r350" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report", "terseLabel": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r351" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report", "terseLabel": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status", "terseLabel": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r353" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category", "terseLabel": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r352" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current", "terseLabel": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company", "terseLabel": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business", "terseLabel": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r348" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r347" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r349" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.shattucklabs.com/role/COVER" ], "xbrltype": "tradingSymbolItemType" }, "sttk_A2020EmployeeStockPurchasePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Employee Stock Purchase Plan", "label": "2020 Employee Stock Purchase Plan [Member]", "terseLabel": "2020 Employee Stock Purchase Plan" } } }, "localname": "A2020EmployeeStockPurchasePlanMember", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "domainItemType" }, "sttk_A2020StockIncentivePlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "2020 Stock Incentive Plan", "label": "2020 Stock Incentive Plan [Member]", "terseLabel": "2020 Stock Incentive Plan" } } }, "localname": "A2020StockIncentivePlanMember", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "domainItemType" }, "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent": { "auth_ref": [], "calculation": { "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails": { "order": null, "parentTag": null, "root": true, "weight": null }, "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Liabilities and Other Liabilities, Current", "label": "Accrued Liabilities and Other Liabilities, Current", "terseLabel": "Accrued expenses and other current liabilities", "totalLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesAndOtherLiabilitiesCurrent", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails", "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "sttk_AccruedResearchAndContractCostsCurrent": { "auth_ref": [], "calculation": { "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails": { "order": 2.0, "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accrued Research And Contract Costs, Current", "label": "Accrued Research And Contract Costs, Current", "terseLabel": "Research and development contract costs" } } }, "localname": "AccruedResearchAndContractCostsCurrent", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "sttk_BlackScholesOptionPricingModelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Black-Scholes Option Pricing Model", "label": "Black-Scholes Option Pricing Model [Member]", "terseLabel": "Black-Scholes Option Pricing Model" } } }, "localname": "BlackScholesOptionPricingModelMember", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "domainItemType" }, "sttk_CommonStockAdditionalCapitalSharesReservedForFutureIssuance": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Common Stock, Additional Capital Shares Reserved for Future Issuance", "label": "Common Stock, Additional Capital Shares Reserved for Future Issuance", "terseLabel": "Common stock, additional capital shares reserved for future issuance (in shares)" } } }, "localname": "CommonStockAdditionalCapitalSharesReservedForFutureIssuance", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "sttk_LicenseAgreementRoyaltyPaymentsMaximum": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "License Agreement, Royalty Payments, Maximum", "label": "License Agreement, Royalty Payments, Maximum", "terseLabel": "License agreement, maximum payment" } } }, "localname": "LicenseAgreementRoyaltyPaymentsMaximum", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "sttk_MonteCarloOptionPricingModelMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Monte Carlo Option Pricing Model", "label": "Monte Carlo Option Pricing Model [Member]", "terseLabel": "Monte Carlo Option Pricing Model" } } }, "localname": "MonteCarloOptionPricingModelMember", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "domainItemType" }, "sttk_NumberOfClinicalStageProductCandidates": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number Of Clinical-stage Product Candidates", "label": "Number Of Clinical-stage Product Candidates", "terseLabel": "Number of clinical-stage product candidate" } } }, "localname": "NumberOfClinicalStageProductCandidates", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "integerItemType" }, "sttk_OperatingAccountMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Operating Account", "label": "Operating Account [Member]", "terseLabel": "Operating Account" } } }, "localname": "OperatingAccountMember", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "sttk_OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Operating Lease Liabilities Recognized For Operating Lease Right-of-Use Assets", "label": "Operating Lease Liabilities Recognized For Operating Lease Right-of-Use Assets", "terseLabel": "Operating lease liabilities recognized for operating right-of-use assets" } } }, "localname": "OperatingLeaseLiabilitiesRecognizedForOperatingLeaseRightOfUseAssets", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "sttk_RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Revenue From Contract With Customer, Deferred Revenue Billed Not Received", "label": "Revenue From Contract With Customer, Deferred Revenue Billed Not Received", "terseLabel": "Deferred revenue billed but not received" } } }, "localname": "RevenueFromContractWithCustomerDeferredRevenueBilledNotReceived", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Annual Increase In Number of Shares Authorized, Term", "terseLabel": "Annual increase in number of shares authorized, term" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAnnualIncreaseInNumberOfSharesAuthorizedTerm", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Grants in Period", "terseLabel": "Share-based payment award, grants in period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardGrantsInPeriod", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Increase In Number of Shares Authorized, Annual Increase Percentage", "terseLabel": "Increase in number of shares authorized, percentage of capital stock outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardIncreaseInNumberOfSharesAuthorizedAnnualIncreasePercentage", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "pureItemType" }, "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Maximum Shares Per Employee, Value", "terseLabel": "Maximum value of shares per employee during any calendar year" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumSharesPerEmployeeValue", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Tranches", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number Of Tranches", "terseLabel": "Number of tranches" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfTranches", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "integerItemType" }, "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Options Exercised And ESPP Purchased in Period", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options Exercises And ESPP Purchases in Period", "terseLabel": "Exercise of stock options and purchases pursuant to employee stock purchase plan (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesAndESPPPurchasesInPeriod", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "sttk_ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Consecutive Trading Days", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Vested and Expected to Vest, Threshold Consecutive Trading Days", "terseLabel": "Threshold consecutive trading days" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardVestedAndExpectedToVestThresholdConsecutiveTradingDays", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "sttk_StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased", "label": "Stock Issued During Period, Value, Stock Options Exercised And ESPP Purchased", "terseLabel": "Exercise of stock options and purchases pursuant to employee stock purchase plan" } } }, "localname": "StockIssuedDuringPeriodValueStockOptionsExercisedAndESPPPurchased", "nsuri": "http://www.shattucklabs.com/20230331", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses and Other Current Liabilities" } } }, "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilities" ], "xbrltype": "textBlockItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r9", "r346" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": { "auth_ref": [ "r33" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.", "label": "Accretion (Amortization) of Discounts and Premiums, Investments", "negatedTerseLabel": "Net amortization (accretion) of investments" } } }, "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedRoyaltiesCurrentAndNoncurrent": { "auth_ref": [ "r81", "r91" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.", "label": "Accrued Royalties", "terseLabel": "Accrued royalty" } } }, "localname": "AccruedRoyaltiesCurrentAndNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "auth_ref": [ "r18", "r19", "r20", "r102", "r321", "r328", "r329" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.", "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax", "terseLabel": "Accumulated other comprehensive loss" } } }, "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r17", "r20", "r74", "r284", "r324", "r325", "r355", "r356", "r357", "r364", "r365", "r366" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]", "terseLabel": "Accumulated Other Comprehensive Gain (Loss)" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapital": { "auth_ref": [ "r4", "r346" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.", "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r259", "r260", "r261", "r364", "r365", "r366", "r404" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-In Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Decrease for Tax Withholding Obligation", "negatedTerseLabel": "Shares withheld related to net share settlement" } } }, "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r68", "r69", "r225" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operations:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r254" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Total stock-based compensation" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r137" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of net loss per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]", "terseLabel": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]", "terseLabel": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r79", "r86", "r101", "r116", "r149", "r158", "r162", "r173", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r265", "r267", "r274", "r346", "r374", "r375", "r408" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r97", "r103", "r116", "r173", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r265", "r267", "r274", "r346", "r374", "r375", "r408" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "auth_ref": [ "r168", "r180" ], "calculation": { "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "totalLabel": "Amortized Cost" } } }, "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "auth_ref": [ "r49", "r167", "r180", "r317" ], "calculation": { "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails": { "order": 1.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale", "terseLabel": "Total Fair Value" } } }, "localname": "AvailableForSaleSecuritiesDebtSecurities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "auth_ref": [ "r48", "r180" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.", "label": "Debt Securities, Available-for-Sale, Current", "terseLabel": "Investments" } } }, "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]", "terseLabel": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]", "terseLabel": "Basis of Presentation and Unaudited Interim Condensed Financial Statements" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CapitalExpendituresIncurredButNotYetPaid": { "auth_ref": [ "r36", "r37", "r38" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "label": "Capital Expenditures Incurred but Not yet Paid", "terseLabel": "Unpaid amounts related to purchases of property and equipment" } } }, "localname": "CapitalExpendituresIncurredButNotYetPaid", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r34", "r99", "r333" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails", "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsAxis": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cash and cash equivalent balance.", "label": "Cash and Cash Equivalents [Axis]", "terseLabel": "Cash and Cash Equivalents [Axis]" } } }, "localname": "CashAndCashEquivalentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Cash and Cash Equivalents [Line Items]", "terseLabel": "Cash and Cash Equivalents [Line Items]" } } }, "localname": "CashAndCashEquivalentsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy": { "auth_ref": [ "r35" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents with respect to unrestricted balances.", "label": "Cash and Cash Equivalents, Unrestricted Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents" } } }, "localname": "CashAndCashEquivalentsUnrestrictedCashAndCashEquivalentsPolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsAndShortTermInvestments": { "auth_ref": [ "r354" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.", "label": "Cash, Cash Equivalents, and Short-Term Investments", "terseLabel": "Cash, cash equivalents, and short-term investments" } } }, "localname": "CashCashEquivalentsAndShortTermInvestments", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r28", "r34", "r39" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of period", "periodStartLabel": "Cash and cash equivalents, beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r28", "r77" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r14", "r82", "r90" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies (Note 5)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "localname": "CommitmentsAndContingenciesDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r54", "r186", "r187", "r330", "r373" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CommitmentsandContingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": { "auth_ref": [ "r55", "r331" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.", "label": "Commitments and Contingencies, Policy [Policy Text Block]", "terseLabel": "Commitments and Contingencies" } } }, "localname": "CommitmentsAndContingenciesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Aggregate number of common shares reserved for future issuance.", "label": "Common Stock, Capital Shares Reserved for Future Issuance", "terseLabel": "Shares reserved for future issuance" } } }, "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r364", "r365", "r404" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]", "terseLabel": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical", "http://www.shattucklabs.com/role/EquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical", "http://www.shattucklabs.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r3", "r56" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETSParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r3", "r346" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "terseLabel": "Common stock, $0.0001 par value: 300,000,000 shares authorized; 42,460,258 shares issued and outstanding at March\u00a031, 2023 and 42,390,586 shares issued and outstanding at December\u00a031, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r21", "r105", "r107", "r111", "r318", "r322" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for comprehensive income.", "label": "Comprehensive Income, Policy [Policy Text Block]", "terseLabel": "Other Comprehensive Income (Loss)" } } }, "localname": "ComprehensiveIncomePolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ConcentrationRiskCreditRisk": { "auth_ref": [ "r85", "r143" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for credit risk.", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "terseLabel": "Concentration of Risk" } } }, "localname": "ConcentrationRiskCreditRisk", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Debt Securities [Abstract]", "terseLabel": "Investments:" } } }, "localname": "DebtSecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax": { "auth_ref": [], "calculation": { "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails": { "order": 2.0, "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, before tax, of unrealized gain (loss) in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain (Loss), before Tax", "terseLabel": "Gross Unrealized Loss" } } }, "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "auth_ref": [ "r171" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table]", "terseLabel": "Debt Securities, Available-for-sale [Table]" } } }, "localname": "DebtSecuritiesAvailableForSaleTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": { "auth_ref": [ "r367" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).", "label": "Debt Securities, Available-for-Sale [Table Text Block]", "terseLabel": "Schedule of investments" } } }, "localname": "DebtSecuritiesAvailableForSaleTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/InvestmentsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_DebtSecuritiesAvailableForSaleTerm": { "auth_ref": [ "r405" ], "lang": { "en-us": { "role": { "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Debt Securities, Available-for-Sale, Term", "terseLabel": "Debt securities, average maturity term" } } }, "localname": "DebtSecuritiesAvailableForSaleTerm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/InvestmentsNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_Depreciation": { "auth_ref": [ "r32", "r51" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.", "label": "Depreciation", "terseLabel": "Depreciation" } } }, "localname": "Depreciation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r227", "r255", "r256", "r258", "r262", "r343" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensation" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Abstract]" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r112", "r122", "r123", "r124", "r125", "r126", "r130", "r132", "r134", "r135", "r136", "r138", "r272", "r273", "r319", "r323", "r336" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Net loss per share \u2013 basic (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r112", "r122", "r123", "r124", "r125", "r126", "r132", "r134", "r135", "r136", "r138", "r272", "r273", "r319", "r323", "r336" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Net loss per share \u2013 diluted (in dollars per share)" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r41", "r42" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Net Loss Per Share" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails": { "order": 3.0, "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Employee-related Liabilities, Current", "terseLabel": "Compensation and related benefits" } } }, "localname": "EmployeeRelatedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "auth_ref": [ "r257" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted-average amortization period" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "auth_ref": [ "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost for RSU" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "auth_ref": [ "r403" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized compensation cost" } } }, "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_EmployeeStockMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.", "label": "Employee Stock [Member]", "terseLabel": "ESPP" } } }, "localname": "EmployeeStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Share-Based Payment Arrangement, Option [Member]", "terseLabel": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails", "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Equity [Abstract]" } } }, "localname": "EquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r56", "r95", "r108", "r109", "r110", "r117", "r118", "r119", "r121", "r127", "r129", "r139", "r174", "r212", "r259", "r260", "r261", "r263", "r264", "r271", "r275", "r276", "r277", "r278", "r279", "r280", "r284", "r324", "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]", "terseLabel": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.", "label": "Fair Value Measurement, Policy [Policy Text Block]", "terseLabel": "Fair Value of Financial Instruments" } } }, "localname": "FairValueMeasurementPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_FinancialInstrumentAxis": { "auth_ref": [ "r169", "r170", "r175", "r176", "r177", "r178", "r179", "r181", "r182", "r183", "r197", "r210", "r269", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r339", "r368", "r369", "r370", "r413", "r414", "r415", "r416", "r417", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Information by type of financial instrument.", "label": "Financial Instrument [Axis]", "terseLabel": "Financial Instrument [Axis]" } } }, "localname": "FinancialInstrumentAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r24" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r23" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the impairment and disposal of long-lived assets including goodwill and other intangible assets.", "label": "Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]", "terseLabel": "Impairment of Long-Lived Assets" } } }, "localname": "ImpairmentOrDisposalOfLongLivedAssetsIncludingIntangibleAssetsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r184", "r185" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]", "terseLabel": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r185" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]", "terseLabel": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r31" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r31" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 9.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": { "auth_ref": [ "r315", "r360" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.", "label": "Increase (Decrease) in Contract with Customer, Liability", "terseLabel": "Deferred revenue" } } }, "localname": "IncreaseDecreaseInContractWithCustomerLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": { "auth_ref": [ "r360", "r407" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 11.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in obligation for operating lease.", "label": "Increase (Decrease) in Operating Lease Liability", "terseLabel": "Non-current operating lease liabilities" } } }, "localname": "IncreaseDecreaseInOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOtherOperatingAssets": { "auth_ref": [ "r31" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in operating assets classified as other.", "label": "Increase (Decrease) in Other Operating Assets", "negatedTerseLabel": "Other assets" } } }, "localname": "IncreaseDecreaseInOtherOperatingAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "auth_ref": [ "r31" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 10.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_InvestmentPolicyTextBlock": { "auth_ref": [ "r172", "r412" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for investment in financial asset.", "label": "Investment, Policy [Policy Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "auth_ref": [ "r50", "r78", "r84", "r93", "r332" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for investments in certain debt and equity securities.", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "terseLabel": "Investments" } } }, "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/Investments" ], "xbrltype": "textBlockItemType" }, "us-gaap_LesseeLeasesPolicyTextBlock": { "auth_ref": [ "r282" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.", "label": "Lessee, Leases [Policy Text Block]", "terseLabel": "Leases" } } }, "localname": "LesseeLeasesPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r11", "r116", "r173", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r266", "r267", "r268", "r274", "r337", "r374", "r408", "r409" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r8", "r80", "r88", "r346", "r363", "r371", "r406" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "Liabilities and Stockholders\u2019 Equity" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r13", "r98", "r116", "r173", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r266", "r267", "r268", "r274", "r346", "r374", "r408", "r409" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "Liabilities, Current", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_LitigationReserveCurrent": { "auth_ref": [ "r14", "r372" ], "calculation": { "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails": { "order": 4.0, "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position.", "label": "Estimated Litigation Liability, Current", "terseLabel": "Litigation settlement" } } }, "localname": "LitigationReserveCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount awarded to other party in judgment or settlement of litigation.", "label": "Litigation Settlement, Amount Awarded to Other Party", "terseLabel": "Litigation settlement, amount awarded to other party" } } }, "localname": "LitigationSettlementAmountAwardedToOtherParty", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_MoneyMarketFundsMember": { "auth_ref": [ "r376" ], "lang": { "en-us": { "role": { "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.", "label": "Money Market Funds [Member]", "terseLabel": "Money Market Funds" } } }, "localname": "MoneyMarketFundsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r140", "r146" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]", "terseLabel": "Organization and Description of Business" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusiness" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r114" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r114" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "Net Cash Provided by (Used in) Investing Activities", "totalLabel": "Net cash provided by (used in) investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]", "terseLabel": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r28", "r30", "r33" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r22", "r33", "r83", "r92", "r96", "r104", "r106", "r110", "r116", "r120", "r122", "r123", "r124", "r125", "r128", "r129", "r133", "r149", "r157", "r161", "r163", "r173", "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r273", "r274", "r338", "r374" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net Income (Loss) Attributable to Parent", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS", "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recently Adopted Accounting Pronouncements" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Expense from operations" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r149", "r157", "r161", "r163", "r338" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r281" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating Lease, Liability, Noncurrent", "terseLabel": "Non-current operating lease liabilities" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "auth_ref": [ "r361" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of amortization expense for right-of-use asset from operating lease.", "label": "Operating Lease, Right-of-Use Asset, Amortization Expense", "terseLabel": "Non-cash operating lease expense" } } }, "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r1", "r40", "r46", "r75" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]", "terseLabel": "Basis of Presentation and Summary of Significant Accounting Policies" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "auth_ref": [ "r12" ], "calculation": { "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails": { "order": 1.0, "parentTag": "sttk_AccruedLiabilitiesAndOtherLiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.", "label": "Other Accrued Liabilities, Current", "terseLabel": "Other current liabilities" } } }, "localname": "OtherAccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesScheduleofaccruedexpensesandothercurrentliabilitiesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherAssetsNoncurrent": { "auth_ref": [ "r100" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncurrent assets classified as other.", "label": "Other Assets, Noncurrent", "terseLabel": "Other assets" } } }, "localname": "OtherAssetsNoncurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r71", "r72", "r73" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities, attributable to parent entity. Excludes amounts related to other than temporary impairment (OTTI) loss.", "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent", "terseLabel": "Unrealized gain on investments", "verboseLabel": "Unrealized gain on investments" } } }, "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r25" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other Nonoperating Income (Expense)", "terseLabel": "Other income (expense)" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PayablesAndAccrualsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Payables and Accruals [Abstract]" } } }, "localname": "PayablesAndAccrualsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm": { "auth_ref": [ "r358", "r359", "r362" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow (inflow) through acquisition (sale) of short-term available-for-sale securities.", "label": "Payments for (Proceeds from) Available-for-Sale Securities, Short-Term", "negatedTerseLabel": "Net change in investments" } } }, "localname": "PaymentsForProceedsFromAvailableforsaleSecuritiesShortterm", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsForRoyalties": { "auth_ref": [ "r29" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash paid for royalties during the current period.", "label": "Payments for Royalties", "terseLabel": "Payments for royalties" } } }, "localname": "PaymentsForRoyalties", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CommitmentsandContingenciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "auth_ref": [ "r113" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards" } } }, "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r26" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "Payments to Acquire Property, Plant, and Equipment", "negatedTerseLabel": "Purchases of property and equipment" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_PlanNameAxis": { "auth_ref": [ "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Information by plan name for share-based payment arrangement.", "label": "Plan Name [Axis]", "terseLabel": "Plan Name [Axis]" } } }, "localname": "PlanNameAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_PlanNameDomain": { "auth_ref": [ "r377", "r378", "r379", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r388", "r389", "r390", "r391", "r392", "r393", "r394", "r395", "r396", "r397", "r398", "r399", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Plan name for share-based payment arrangement.", "label": "Plan Name [Domain]", "terseLabel": "Plan Name [Domain]" } } }, "localname": "PlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r2", "r198" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/EquityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/EquityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r354" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid Expense and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "auth_ref": [ "r27", "r67" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "terseLabel": "Proceeds from the exercises of stock options and purchases pursuant to employee stock purchase plan" } } }, "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromStockPlans": { "auth_ref": [ "r27" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received from the stock plan during the period.", "label": "Proceeds from Stock Plans", "terseLabel": "Proceeds from ESPP" } } }, "localname": "ProceedsFromStockPlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r52", "r89", "r320", "r346" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Property, Plant and Equipment, Net", "terseLabel": "Property and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r70", "r94", "r410" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ResearchAndDevelopmentExpensePolicy": { "auth_ref": [ "r70" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.", "label": "Research and Development Expense, Policy [Policy Text Block]", "terseLabel": "Research and Development Costs" } } }, "localname": "ResearchAndDevelopmentExpensePolicy", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "auth_ref": [ "r99" ], "lang": { "en-us": { "role": { "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash and Cash Equivalents [Domain]", "terseLabel": "Cash and Cash Equivalents [Domain]" } } }, "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockMember": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.", "label": "Restricted Stock [Member]", "terseLabel": "Unvested restricted stock" } } }, "localname": "RestrictedStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RestrictedStockUnitsRSUMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "label": "Restricted Stock Units (RSUs) [Member]", "terseLabel": "Restricted Stock Units (RSUs)" } } }, "localname": "RestrictedStockUnitsRSUMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r5", "r57", "r87", "r327", "r329", "r346" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "negatedTerseLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS", "http://www.shattucklabs.com/role/OrganizationandDescriptionofBusinessDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r95", "r117", "r118", "r119", "r121", "r127", "r129", "r174", "r259", "r260", "r261", "r263", "r264", "r271", "r324", "r326" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "domainItemType" }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "auth_ref": [ "r147", "r148", "r156", "r159", "r160", "r164", "r165", "r166", "r221", "r222", "r316" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS": { "order": 2.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Collaboration revenue" } } }, "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "monetaryItemType" }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "auth_ref": [ "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r223", "r334" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for revenue from contract with customer.", "label": "Revenue from Contract with Customer [Policy Text Block]", "terseLabel": "Revenue Recognition" } } }, "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "auth_ref": [ "r340" ], "lang": { "en-us": { "role": { "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer.", "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "terseLabel": "Revenue from Contract with Customer, Product and Service [Extensible List]" } } }, "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "enumerationSetItemType" }, "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": { "auth_ref": [ "r283", "r345" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.", "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability", "terseLabel": "Operating right-of-use assets exchanged for operating lease liabilities" } } }, "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of accrued liabilities.", "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses and other current liabilities" } } }, "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/AccruedExpensesandOtherCurrentLiabilitiesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesScheduleofantidilutivesecuritiesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "auth_ref": [ "r41" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of antidilutive securities excluded from computation of net loss per share" } } }, "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Debt Securities, Available-for-Sale [Line Items]", "terseLabel": "Debt Securities, Available-for-sale [Line Items]" } } }, "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfCashAndCashEquivalentsTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Schedule of cash and cash equivalent balances. This table excludes restricted cash balances.", "label": "Schedule of Cash and Cash Equivalents [Table]", "terseLabel": "Schedule of Cash and Cash Equivalents [Table]" } } }, "localname": "ScheduleOfCashAndCashEquivalentsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "auth_ref": [ "r65" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense" } } }, "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfOtherShareBasedCompensationActivityTableTextBlock": { "auth_ref": [ "r60" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of activity for outstanding award under share-based payment arrangement excluding share and unit options and nonvested award.", "label": "Share-Based Payment Arrangement, Outstanding Award, Activity, Excluding Option [Table Text Block]", "terseLabel": "Schedule of RSU activity" } } }, "localname": "ScheduleOfOtherShareBasedCompensationActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r224", "r226", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "auth_ref": [ "r59", "r61", "r62" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of option activity" } } }, "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "auth_ref": [ "r64" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of valuation assumptions" } } }, "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "auth_ref": [ "r150", "r151", "r152", "r153", "r154", "r155", "r165" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for segment reporting.", "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information" } } }, "localname": "SegmentReportingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r31" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "auth_ref": [ "r343" ], "lang": { "en-us": { "role": { "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Stock-based compensation, vesting period" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "negatedTerseLabel": "Forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "auth_ref": [ "r244" ], "lang": { "en-us": { "role": { "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "terseLabel": "Forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r242" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "auth_ref": [ "r239", "r240" ], "lang": { "en-us": { "role": { "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "periodEndLabel": "Awards, ending balance (in shares)", "periodStartLabel": "Awards, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "auth_ref": [ "r239", "r240" ], "lang": { "en-us": { "role": { "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "periodEndLabel": "Ending balance (in dollars per share)", "periodStartLabel": "Beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]", "terseLabel": "Weighted Average Grant Date Fair Value" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "negatedTerseLabel": "Awards, vested (in shares)", "verboseLabel": "Issuance of common stock upon settlement of restricted stock units (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r243" ], "lang": { "en-us": { "role": { "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Vested (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "auth_ref": [ "r251" ], "lang": { "en-us": { "role": { "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividends" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofstockbasedcompensationexpenseDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "The highest percentage of annual salary that an employee is permitted to utilize with respect to the plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Employee Subscription Rate", "terseLabel": "Contribution limit in percentage of employee's eligible compensation" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumEmployeeSubscriptionRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "The highest quantity of shares an employee can purchase under the plan per period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee", "terseLabel": "Maximum number of shares per employee during any one purchase period (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Options, exercisable (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, exercisable (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "auth_ref": [ "r246" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "terseLabel": "Intrinsic value of options exercised" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedTerseLabel": "Options, forfeited (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Options, granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "auth_ref": [ "r245" ], "lang": { "en-us": { "role": { "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Grant date fair value (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of options outstanding" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "auth_ref": [ "r231", "r232" ], "lang": { "en-us": { "role": { "documentation": "Number of options outstanding, including both vested and non-vested options.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Options, ending balance (in shares)", "periodStartLabel": "Options, beginning balance (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r231", "r232" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Weighted average exercise price, ending balance (in dollars per share)", "periodStartLabel": "Weighted average exercise price, beginning balance (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number", "terseLabel": "Options, vested and expected to vest (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, vested and expected to vest (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]", "terseLabel": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofrestrictedstockactivityDetails", "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, exercised (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, forfeited (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Weighted average exercise price, granted (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "auth_ref": [ "r344" ], "lang": { "en-us": { "role": { "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Share-based compensation, expiration period" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected term - years" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "auth_ref": [ "r66" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Aggregate intrinsic value of options exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r66" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted\u00a0average remaining contract life, exercisable" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "auth_ref": [ "r63" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted\u00a0average remaining contract life, outstanding" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": { "auth_ref": [ "r247" ], "lang": { "en-us": { "role": { "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Weighted\u00a0average remaining contract life, vested and expected to vest" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "durationItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Purchase price of common stock expressed as a percentage of its fair value.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent", "terseLabel": "Purchase price of common stock in percent" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "percentItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Ending balance (in shares)", "periodStartLabel": "Beginning balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.", "label": "Share-Based Payment Arrangement, Shares Withheld for Tax Withholding Obligation", "negatedTerseLabel": "Shares withheld related to net share settlement (in shares)" } } }, "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r16", "r56", "r95", "r108", "r109", "r110", "r117", "r118", "r119", "r121", "r127", "r129", "r139", "r174", "r212", "r259", "r260", "r261", "r263", "r264", "r271", "r275", "r276", "r277", "r278", "r279", "r280", "r284", "r324", "r325", "r326" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]", "terseLabel": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r117", "r118", "r119", "r139", "r316" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]", "terseLabel": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": { "auth_ref": [ "r2", "r3", "r56", "r57" ], "lang": { "en-us": { "role": { "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.", "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans", "terseLabel": "Stock issued under ESPP (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationNarrativeDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r2", "r3", "r56", "r57", "r236" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Options, exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofoptionactivityDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r3", "r6", "r7", "r47", "r346", "r363", "r371", "r406" ], "calculation": { "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS": { "order": 3.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS", "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCHANGESINSTOCKHOLDERSEQUITY" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders\u2019 equity:" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDBALANCESHEETS" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r58", "r115", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r211", "r212", "r270" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "Equity" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/Equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SupplementalCashFlowInformationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosures of non-cash financial activities:" } } }, "localname": "SupplementalCashFlowInformationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFCASHFLOWS" ], "xbrltype": "stringItemType" }, "us-gaap_TangibleAssetImpairmentCharges": { "auth_ref": [ "r0", "r53" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The charge against earnings resulting from the aggregate write down of tangible assets from their carrying value to their fair value.", "label": "Tangible Asset Impairment Charges", "terseLabel": "Impairment of long-lived assets" } } }, "localname": "TangibleAssetImpairmentCharges", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesNarrativeDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "auth_ref": [ "r169", "r170", "r197", "r210", "r269", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r298", "r299", "r300", "r301", "r302", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r368", "r369", "r370", "r413", "r414", "r415", "r416", "r417", "r418", "r419" ], "lang": { "en-us": { "role": { "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.", "label": "Financial Instruments [Domain]", "terseLabel": "Financial Instruments [Domain]" } } }, "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_USTreasurySecuritiesMember": { "auth_ref": [ "r335", "r341", "r342", "r411" ], "lang": { "en-us": { "role": { "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).", "label": "US Treasury Securities [Member]", "terseLabel": "U.S. Treasury securities" } } }, "localname": "USTreasurySecuritiesMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/InvestmentsScheduleofavailableforsaleinvestmentsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r43", "r44", "r45", "r141", "r142", "r144", "r145" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/BasisofPresentationandSummaryofSignificantAccountingPoliciesPolicies" ], "xbrltype": "textBlockItemType" }, "us-gaap_ValuationTechniqueAxis": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Information by valuation approach and technique.", "label": "Valuation Approach and Technique [Axis]", "terseLabel": "Valuation Approach and Technique [Axis]" } } }, "localname": "ValuationTechniqueAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ValuationTechniqueDomain": { "auth_ref": [ "r76" ], "lang": { "en-us": { "role": { "documentation": "Valuation approach and technique.", "label": "Valuation Approach and Technique [Domain]", "terseLabel": "Valuation Approach and Technique [Domain]" } } }, "localname": "ValuationTechniqueDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/StockBasedCompensationScheduleofvaluationassumptionsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r131", "r136" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted-average shares outstanding \u2013 diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r130", "r136" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted-average shares outstanding \u2013 basic (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.shattucklabs.com/role/CONDENSEDSTATEMENTSOFOPERATIONSANDCOMPREHENSIVELOSS" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a),20,24)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(17))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "29", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8864-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "5A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "1I", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130543-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "606", "URI": "https://asc.fasb.org/topic&trid=49130388", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918666-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(2)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)(ii)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)(i)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(4)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(5)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(6)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(a)(7)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(b)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(1)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(2)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "50", "Subparagraph": "(e)(3)", "Topic": "860", "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=126938201&loc=d3e55415-109406", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(6))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(ii)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "450", "Topic": "954", "URI": "https://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1403", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "30", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "91", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "606", "URI": "https://asc.fasb.org/extlink&oid=126920602&loc=SL49130690-203046-203046", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r347": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r348": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r349": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r351": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r352": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r353": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4304-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3098-108585", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r367": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4313-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "321", "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r373": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org/topic&trid=2127136", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4332-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org/topic&trid=2122369", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "320", "Subparagraph": "(b)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(3)(b))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r413": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(a)", "Publisher": "SEC", "Section": "1402", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r414": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(1)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r415": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r416": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(b)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(3)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r417": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(i)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r418": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(ii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r419": { "Name": "Regulation S-K (SK)", "Number": "229", "Paragraph": "(c)", "Publisher": "SEC", "Section": "1402", "Subparagraph": "(2)(iii)", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org/topic&trid=2134479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(aa)", "Topic": "320", "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "320", "URI": "https://asc.fasb.org/topic&trid=2196928", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "360", "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org/topic&trid=2144648", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "460", "URI": "https://asc.fasb.org/extlink&oid=126907703&loc=d3e12565-110249", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "2A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569643-111683", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r75": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r78": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "940", "URI": "https://asc.fasb.org/subtopic&trid=2176304", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.15(5))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r84": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "942", "URI": "https://asc.fasb.org/subtopic&trid=2209399", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "825", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.15(a))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r93": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "SubTopic": "320", "Topic": "946", "URI": "https://asc.fasb.org/subtopic&trid=2324412", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 49 0001680367-23-000035-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001680367-23-000035-xbrl.zip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end